Exhibit 10.1
 

 

 

 
STOCK PURCHASE AGREEMENT
 
BY AND AMONG
 
ELK VALLEY PROFESSIONAL AFFILIATES, INC.,
a Tennessee corporation,
 
SOUTH MISSISSIPPI HOME HEALTH, INC.,
a Mississippi corporation,
 
DEACONESS HOMECARE, LLC,
a Delaware limited liability company,
 
BIOSCRIP, INC.
a Delaware corporation,
 
THE BUYERS IDENTIFIED ON THE SIGNATURE PAGE HERETO,
 
and
 
LHC GROUP, INC.
a Delaware corporation
 

 
February 1, 2014
 
 
 

--------------------------------------------------------------------------------

 
Table of Contents
 
Page
 
ARTICLE 1 DEFINITIONS
2
1.1
Certain Definitions
2
1.2
Other Defined Terms
9
   
ARTICLE 2 SALE AND PURCHASE OF SHARES
10
   
ARTICLE 3 CLOSING
10
   
ARTICLE 4 PURCHASE PRICE
10
4.1
Purchase Price
10
4.2
Payment and Adjustment of Purchase Price
11
   
ARTICLE 5 REPRESENTATIONS AND WARRANTIES RELATING TO THE COMPANIES
12
   
5.1
Organization and Corporate Power
12
5.2
Authorization; Valid and Binding Agreement
12
5.3
No Breach
12
5.4
Capitalization.
13
5.5
Financial Statements
14
5.6
Absence of Certain Developments
15
5.7
Title to Properties
15
5.8
Real Property.
15
5.9
Tax Matters
16
5.10
Contracts and Commitments.
18
5.11
Intellectual Property
19
5.12
Litigation
20
5.13
Employee Benefit Plans.
20
5.14
Insurance
21
5.15
Compliance with Laws
21
5.16
Environmental Matters
21
5.17
Related Party Transactions
22
5.18
Employees.
22
5.19
Brokerage
23
5.20
Licenses, Authorizations and Provider Programs
24
5.21
Officers and Directors
25
5.22
Bank Accounts
25
5.23
Healthcare Laws.
25
5.24
Inspections and Investigations
26
5.25
Suppliers
27
5.26
No Undisclosed Liabilities
27
5.27
No Other Representations or Warranties
27
   

 
 
i

--------------------------------------------------------------------------------

 
ARTICLE 6 REPRESENTATIONS AND WARRANTIES OF SHAREHOLDER
27
   
6.1
Organization and Authority
27
6.2
Authorization; Valid and Binding Agreement
27
6.3
No Breach
28
6.4
Litigation
28
6.5
Title to Shares, Etc.
28
6.6
Brokerage
28
6.7
No Other Representations or Warranties
28
   
ARTICLE 7 REPRESENTATIONS AND WARRANTIES OF BUYER
29
   
7.1
Organization and Authority
29
7.2
Authorization; Valid and Binding Agreement
29
7.3
Brokerage
29
7.4
Litigation
29
7.5
Financing
29
7.6
No Knowledge of Misrepresentations or Omissions
29
7.7
No Other Representations or Warranties
29
   
ARTICLE 8 BUYER’S CONDITIONS PRECEDENT TO CLOSING
30
   
8.1
Covenants to be Performed
30
8.2
No Judgment, Decree or Order
30
8.3
Supporting Documents
30
8.4
Satisfaction of Indebtedness; Release of Liens
31
8.5
Third Party Consents
31
8.6
No Material Adverse Effect
31
8.7
Necessary Consents and Approvals
31
8.8
Transfer of Assets to Operating Newcos
31
   
ARTICLE 9 SHAREHOLDER’S CONDITIONS PRECEDENT TO CLOSING
31
   
9.1
Covenants to be Performed
31
9.2
No Judgment, Decree or Order
31
9.3
Supporting Documents
31
9.4
Purchase Price
32
   
ARTICLE 10 PRE-CLOSING COVENANTS
32
   
10.1
Conduct of the Business.
32
10.2
Access to Books and Records
35
10.3
Conditions
36
10.4
Transition Services
36
10.5
No-Shop
36
10.6
Insurance
36
10.7
Resignation of Directors and Officers
37
10.8
Formation of Holding Newcos and Operating Newcos
37
   

 
 
ii

--------------------------------------------------------------------------------

 
ARTICLE 11 COVENANTS OF BUYER
37
   
11.1
Access to Books and Records
37
11.2
Conditions
37
11.3
Contact with Customers, Suppliers, Etc
37
11.4
Confidentiality
38
11.5
Employment; Employee Benefits
38
11.6
WARN Act Notice
39
11.7
Notification
39
   
ARTICLE 12 ADDITIONAL COVENANTS AND AGREEMENTS
39
   
12.1
Acknowledgment by Buyer.
39
12.2
Tax Matters.
40
12.3
Further Assurances
45
12.4
Restrictive Covenants
45
12.5
Public Announcements
48
12.6
Access to Books and Records
49
   
ARTICLE 13 INDEMNIFICATION
49
   
13.1
Survival Period
49
13.2
Indemnification by the Shareholder for the Benefit of Buyer.
49
13.3
Mitigation; Related Matters.
51
13.4
Indemnification by Buyer for the Benefit of the Shareholder
52
13.5
Manner of Payment
53
13.6
Defense of Third Party Claims
53
13.7
Determination of Loss Amount
53
13.8
Expiration of Indemnification
54
13.9
Effect of Failure to Close
54
   
ARTICLE 14 TERMINATION
54
   
ARTICLE 15 MISCELLANEOUS
55
   
15.1
Specific Performance
55
15.2
Notices
55
15.3
Waiver
56
15.4
Third Parties
56
15.5
Severability
56
15.6
Amendment
56
15.7
Counterparts
56
15.8
Headings
56
15.9
Entire Agreement
56
15.10
Successors and Assigns
56
15.11
Governing Law; Jurisdiction
56
15.12
BioScrip Guarantee.
57
15.13
LHC Guarantee.
58

 
 
 
iii

--------------------------------------------------------------------------------

 
STOCK PURCHASE AGREEMENT

This STOCK PURCHASE AGREEMENT (this “Agreement”) is entered into as of this 1st
day of February, 2014 (the “Effective Date”), by and among ELK VALLEY
PROFESSIONAL AFFILIATES, INC., a Tennessee corporation (“EVPA”), SOUTH
MISSISSIPPI HOME HEALTH, INC., a Mississippi corporation (“SMHH”) , DEACONESS
HOMECARE, LLC, a Delaware limited liability company (“Shareholder”), and the
Buyers identified on the signature pages hereto (collectively, the “Buyer”),
BioScrip, Inc., a Delaware corporation (“BioScrip”) (solely with respect to
Sections 10.4, 10.5, 10.6, 12.2, 12.4 and 15.12), and LHC Group, a Delaware
corporation (“LHC”) (solely with respect to Sections 10.4, 10.6, 12.3 and
15.13).
 
RECITALS
 
WHEREAS, SMHH owns all of the issued and outstanding shares of the capital stock
of the following: South Mississippi Home Health, Inc. – Region I, a Mississippi
corporation, South Mississippi Home Health, Inc. – Region II, a Mississippi
corporation, South Mississippi Home Health, Inc. – Region III, a Mississippi
corporation, which collectively conduct home health and hospice operations in
the State of Mississippi at the locations set forth on Exhibit A hereto;
 
WHEREAS, EVPA holds all of the membership interests of the following: Cedar
Creek Home Health Care Agency, LLC, a Tennessee limited liability company, Elk
Valley Health Services, LLC, a Tennessee limited liability company, Gericare,
LLC, a Tennessee limited liability company, Elk Valley Home Health Care Agency,
LLC, a Tennessee limited liability company, which collectively conduct home
health and private duty operations in the State of Tennessee at the locations
set forth on Exhibit A hereto;
 
WHEREAS, Infusion Therapy Specialists, Inc., a Nebraska corporation,
Scott-Wilson, Inc., a Kentucky corporation, and Option Health, Ltd., an Illinois
corporation (the “Excluded Companies”), collectively conduct home health
operations in the States of Nebraska, Kentucky and Illinois, respectively, at
the locations set forth on Exhibit A hereto;
 
WHEREAS, prior to the Closing the Shareholder is expected to form three (3) new
wholly owned limited liability company subsidiaries in connection with the
transactions contemplated hereunder  (“Holding Newcos”);
 
WHEREAS, prior to the Closing the Holding Newcos are expected to each form a
wholly owned limited liability company subsidiary in connection with the
transactions contemplated hereunder  (“Operating Newcos”);
 
WHEREAS, prior to the Closing the assets which are currently solely used in, and
the operating liabilities which arose solely from, the operation of the home
health businesses currently operated through the Excluded Companies are expected
to be transferred to the Operating Newcos;
 
WHEREAS, Shareholder owns all of the issued and outstanding shares of the
capital stock of EVPA and SMHH, and prior to the Closing will own all of the
issued and outstanding membership interests of the Holding Newcos (collectively,
the “Shares”); and
 
 
1

--------------------------------------------------------------------------------

 
WHEREAS, Buyer desires to purchase from Shareholder, and Shareholder desires to
sell to Buyer, the Shares on the terms and conditions hereinafter set forth.
 
NOW, THEREFORE, in consideration of the above and the mutual representations,
warranties, covenants and agreements set forth herein, the parties hereby agree
as follows:
 
ARTICLE 1
DEFINITIONS
 
1.1 Certain Definitions.  In this Agreement, the following terms have the
meanings specified or referred to in this Section 1.1, which shall be equally
applicable to both the singular and plural forms.
 
“Affiliate” means a Person that directly, or indirectly through one or more
intermediaries, controls, or is controlled by, or is under common control with,
a specified Person. For purposes of this definition, “control” means the
possession, directly or indirectly, of the power to elect at least 50% of the
governing board of such Person or to direct or cause the direction of the
management and policies of the Person, whether through ownership of voting
securities, partnership or limited liability interests, nonprofit membership,
contract or otherwise.
 
“Buyer Closing Date Transaction” means any transaction outside of the ordinary
course of business engaged in by any Company or any Company Subsidiary on the
Closing Date, which occurs after the Closing at the direction of the Buyer,
including any transaction engaged in by any Company or any Company Subsidiary in
connection with the financing any obligations of the Buyer to make a payment
under this Agreement, but not including transactions deemed to occur as a result
of a Section 338(h)(10) Election.
 
“Closing Date Net Working Capital” means the Net Working Capital as of the
Closing Date as determined in accordance with Section 4.2. For the avoidance of
doubt, the Net Working Capital for each Company and each Company Subsidiary will
be aggregated, however, any asset or Liability on the balance sheet of either
Company related to Company Subsidiaries or any Affiliates shall be disregarded.
 
“Code” means the Internal Revenue Code of 1986, as amended.
 
“Companies’ knowledge”, “knowledge of Companies” and like phrases mean the
actual knowledge of the Companies’ and Companies’ Subsidiaries’ Vice President
of Home Care and Vice President Finance and Treasurer, and BioScrip’s Senior
Vice President Human Resources, Chief Information Officer, Chief Financial
Officer, Director of Corporate Development, and those person(s) identified on
Schedule 1.1 attached hereto, after such due inquiry as a prudent businessperson
would have made or exercised in the management of his or her business affairs.
 
“Companies” means EVPA, SMHH, and Holding Newcos, with each referred to as a
“Company”.
 
“Companies’ Subsidiaries” means Cedar Creek Home Health Care Agency, LLC, a
Tennessee limited liability company, Elk Valley Health Services, LLC, a
Tennessee limited liability company, Gericare, LLC, a Tennessee limited
liability company, Elk Valley Home Health Care Agency, LLC, a Tennessee limited
liability company, South Mississippi Home Health, Inc. – Region I, a Mississippi
corporation, South Mississippi Home Health, Inc. – Region II, a Mississippi
corporation, South Mississippi Home Health, Inc. – Region III, a Mississippi
corporation, and the Operating Newcos (once formed).
 
 
2

--------------------------------------------------------------------------------

 
“Confidential Information” means any confidential or proprietary business
information, other than Trade Secrets, solely applicable to the Companies or the
Companies’ Subsidiaries that is the subject of reasonable efforts to maintain
its confidentiality and that is not generally disclosed by practice or authority
to persons not employed by the Companies or the Companies’
Subsidiaries.  Confidential Information shall include, but not be limited to,
the following to the extent solely applicable to the Companies and the
Companies’ Subsidiaries: (i) business or operating plans, strategies, know-how,
portfolios, prospects or objectives; (ii) structure, products, product
development in progress as of the date hereof, technology, distribution, sales,
advertising services, support and marketing plans, practices, and operations;
(iii) methods of pricing, costs and details of services; (iv) financial
condition and results of operations; (v) the performance of any accounts; (vi)
research and development, operations or plans; (vii) lists of patients, and
payors (including, without limitation, the identity of patients, addresses, and
any other characteristics of such Persons); (viii) information received from
third parties under confidential conditions; (ix) management organization and
related information (including, without limitation, data and other information
concerning the compensation and benefits paid to officers, directors, employees
and management); (x) personnel and compensation policies; (xi) operating
policies and manuals; (xii) financial records and related information; (xiii)
computer aided systems, software, strategies and programs; (xiv) financial data,
formulas, patterns, compilations, studies, strategies, methods, techniques,
processes and system analyses; or (xv) other valuable financial, commercial,
business technical and marketing information  related to any of the products or
services made solely with respect to, the Companies or any of the Companies’
Subsidiaries.  This definition shall not limit any definition of “confidential
information” or any equivalent term under applicable state or federal law as
applied to information which is solely applicable to the Companies or the
Companies’ Subsidiaries. “Confidential Information” shall not include
information which may also pertain to the Shareholder or its Affiliates (other
than the Companies and the Companies’ Subsidiaries).
 
“Current Assets” means all accounts, notes, interest and other receivables of
Companies and the Companies’ Subsidiaries, and all claims, rights, interests and
proceeds related thereto, including all accounts and other receivables, in any
case arising from the rendering of services to patients of the Companies and the
Companies’ Subsidiaries, billed and unbilled, recorded and unrecorded, for
services provided by Companies and the Companies’ Subsidiaries whether payable
by private pay patients, private insurance, third party payors, Medicare,
Medicaid, or by any other source (net of reserves for contractual allowances and
allowance for doubtful accounts), inventory and prepaid expenses, calculated
consistent with past practices.
 
“Current Liabilities” means all accounts payable, accrued Taxes and accrued
wages and related liabilities of the Companies and the Companies’ Subsidiaries,
calculated consistent with past practices.
 
 
3

--------------------------------------------------------------------------------

 
“Dispute” means any dispute or controversy arising between or among any parties
out of or relating to or with respect to any of the provisions contained in this
Agreement.
 
“EBITDA” means earnings before interest, income Taxes, depreciation and
amortization, all of which shall be determined in accordance with GAAP,
calculated consistent with past practices.
 
“Employee Benefit Plans” means each “employee benefit plan” (as such term is
defined in Section 3(3) of ERISA) and each other material employee benefit plan,
program or arrangement that is maintained or contributed to by the Companies or
the Companies’ Subsidiaries on behalf of their employees; provided, however,
that the definition of “Employee Benefit Plan” shall not be deemed to include
employment agreements.
 
“Environmental Laws” means all applicable federal, state, local and foreign Laws
concerning emissions, discharges, releases or threatened releases, or the
manufacture, transportation, storage or use, of any substance that is or becomes
defined as a “hazardous substance,” “hazardous waste,” “hazardous material,”
“pollutant,” or “contaminant” under the Comprehensive Environmental Response
Compensation and Liability Act; the Emergency Planning and Community
Right-To-Know Act; the Toxic Substances Control Act; the Resource Conservation
and Recovery Act; the Clean Water Act; the Safe Drinking Water Act; the Clean
Air Act; and the Hazardous Materials Transportation Act, each as amended and
supplemented as of the Closing Date, any final regulations promulgated pursuant
to such Laws, and any analogous and applicable Law, as the foregoing are enacted
and in effect on or prior to the Closing Date.
 
“GAAP” means generally accepted accounting principles.
 
“Governmental Entity” means any government or any agency, bureau, board,
commission, court, arbitral body, department, division, official, political
subdivision, tribunal or other instrumentality of any government, whether
federal, state or local, domestic or foreign.
 
“Health Care Laws” means: (i) Title XVIII of the Social Security Act, 42 U.S.C.
§§ 1395-1395hhh (the Medicare statute), including specifically, the Ethics in
Patient Referrals Act, as amended (the “Stark Law”), 42 U.S.C. § 1395nn; (ii)
Title XIX of the Social Security Act, 42 U.S.C. §§ 1396-1396v (the Medicaid
statute); (iii) the Federal Health Care Program Anti-Kickback Statute, 42 U.S.C.
§ 1320a-7b(b); (iv) the False Claims Act, 31 U.S.C. §§ 3729-3733 (as amended);
the Program Fraud Civil Remedies Act, 31 U.S.C. §§ 3801-3812; the Anti-Kickback
Act of 1986, 41 U.S.C. §§ 51-58; (v) the Civil Monetary Penalties Law, 42 U.S.C.
§§ 1320a-7a and 1320a-7b; the Exclusion Laws, 42 U.S.C. § 1320a-7; (vi) the
Health Insurance Portability and Accountability Act of 1996, 42 U.S.C. §§
1320d-1329d-8 (“HIPAA”) and all applicable implementing regulations, rules,
ordinances, judgments, and orders, and any similar state and local statutes,
regulations, rules, ordinances, judgments, and orders; (vii) all licensing,
certificate of need, regulatory and reimbursement Laws applicable to healthcare
service providers providing the items and services that the Companies or the
Companies’ Subsidiaries provide, including, without limitation 42 CFR
§424.550(b) referenced in Section 5.23.6 below; and (viii) any applicable
policies, manuals, transmittals, guidelines of Governmental Entities related to
reimbursement, claims submission or claims adjudication (including, without
limiting the generality of the foregoing, any of the same, noncompliance with
which would reasonably be expected to terminate or disqualify a person’s
(including any party hereto) reimbursement or right to payment from, or
participation with, any governmental payor).
 
 
4

--------------------------------------------------------------------------------

 
“Indebtedness” means, without duplication, the sum of (i) all obligations of the
Companies and the Companies’ Subsidiaries for indebtedness for borrowed money
(excluding, for the avoidance of doubt, any trade payables, accounts payable and
other similar liabilities) and (ii) all obligations of the Companies and the
Companies’ Subsidiaries for any accrued but unpaid interest relating to any of
the foregoing; provided that, notwithstanding anything in the foregoing to the
contrary, Indebtedness shall not include any (a) liabilities or obligations of
the Companies and the Companies’ Subsidiaries in respect of any guarantees,
letters of credit, performance bonds, surety bonds, sureties or similar
obligations issued by or on behalf of the Companies or the Companies’
Subsidiaries, whether issued in connection with any customer or supplier
contracts, proposals or otherwise, but in all cases limited to those solely
related to the business operations of the Companies and the Companies’
Subsidiaries, (b) intercompany accounts, payables or loans of any kind or nature
between or among any of the Companies and the Companies’ Subsidiaries, (c)
liabilities or obligations under any lease (including under any capital lease),
and (d) liabilities or obligations of the Companies and/or the Companies’
Subsidiaries relating to Buyer’s and/or any of Buyer’s Affiliates’ financing for
the transactions contemplated hereby and/or any indebtedness arranged by Buyer
and/or any of Buyer’s Affiliates.
 
“Independent Auditor” means BKD, LLP or another independent national or regional
accounting firm which is acceptable to the parties and is not the auditor for
Buyer, Shareholder or their respective Affiliates.
 
“Intellectual Property” means all (i) patents, patent applications, patent
disclosures and inventions, together with all improvements, revisions,
extensions and continuations thereof (ii) trademarks, service marks, trade
dress, trade names, logos and corporate names (in each case, whether registered
or unregistered) and registrations and applications for registration thereof
together, to the extent applicable, with all of the goodwill associated
therewith, (iii) copyrights (registered or unregistered) and registrations and
applications for registration thereof, (iv) computer software, data, data bases
and documentation thereof, (v) trade secrets and other confidential information
(including, without limitation, ideas, formulas, compositions, inventions
(whether patentable or unpatentable and whether or not reduced to practice),
know-how, manufacturing and production processes and techniques, research and
development information, drawings, specifications, designs, plans, proposals,
technical data, copyrightable works, financial and marketing plans and customer
and supplier lists and information), (vi) World Wide Web addresses and domain
name registrations, (vii) works of authorship including, without limitation,
computer programs, source code and executable code, whether embodied in
software, firmware or otherwise, documentation, designs, files, records, data
and mask works and any rights in semiconductor masks, layouts, architectures or
topography, (viii) all advertising and promotional materials, and (ix) all
copies and tangible embodiments of any of the above.
 
“Law” means, with respect to any particular Person, any statute, law, ordinance,
rule or regulation of a Governmental Entity applicable to such Person, as the
case may be.
 
 
5

--------------------------------------------------------------------------------

 
“Liability” means any direct or indirect, primary or secondary, liability,
indebtedness, obligation, penalty, cost or expense (including costs of
investigation, collection and defense), claim, deficiency, guaranty or
endorsement of or by any Person (other than endorsements of notes, bills,
checks, and drafts presented for collection or deposit in the ordinary course of
business) of any type, whether accrued, absolute or contingent, known or
unknown, liquidated or unliquidated, matured or unmatured, or otherwise.
 
“Liens” means any liens, claims, options, pledges, security interests,
encumbrances or restrictions on transfer.
 
“Losses” means losses and out-of-pocket costs, damages, and expenses, including,
without limitation, reasonable legal fees, accounting costs, fines, penalties,
compliance costs, amounts paid in settlement, court costs, investigation and
remediation costs, and consultant, expert, and other professional fees,
including any of the above incurred in enforcing a right to indemnification
hereunder. Losses shall exclude any such items that are punitive, special,
consequential, incidental, exemplary, in the nature of lost profits or the like,
or any dimunition in value of property or equity, except as to actual awards to
a third party in an action brought against a Buyer Indemnified Party or with
respect to a claim based on fraud.
 
“Material Adverse Effect” means any fact, circumstance, effect, change, event or
development that materially adversely affects the business, properties,
condition (financial or otherwise) or results of operations of the Companies and
the Companies’ Subsidiaries, taken as a whole; provided, that, for purposes of
this Agreement, a Material Adverse Effect shall not include the effect of (and
none of the following shall be deemed in themselves, either alone or in
combination, to constitute, and none of the following shall be taken into
account in determining whether there has been or will be, a Material Adverse
Effect) (i) facts or circumstances existing as of the Effective Date within, or
changes to, the industry or markets in which the business of the Companies and
the Companies’ Subsidiaries operate, (ii) the announcement or disclosure of the
transactions contemplated herein, (iii) general economic, regulatory or
political conditions and other economic, regulatory or political conditions
applicable to the home health care industry, or changes to any of the foregoing,
(iv) changes in or the condition of financial, banking or securities markets
(including any disruption thereof and any decline in the price of any security
or any market index), (v) military action or any act of terrorism, (vi) changes
in Law or GAAP after the date hereof, (vii) compliance with the terms of this
Agreement or with any request of Buyer, (viii) any “Act of God”, including, but
not limited to, any hurricane, fire, earthquake or other natural disaster, (ix)
the failure of the Companies and the Companies’ Subsidiaries to meet or achieve
the results set forth in any projection, estimate, forecast or plan, and/or (x)
any matter set forth in the Schedules hereto (provided that the underlying
causes of such failures in subsections (ix) and (x) (subject to the other
provisions of this definition) shall not be excluded), except in each of
subsections (i), (iii), (iv), (v), (vi), and (viii), above, to the extent that
such changes, conditions or acts, taken as a whole, have a disproportionate
impact on the Companies or the Companies’ Subsidiaries relative to other
comparable businesses.
 
“Net Working Capital” means consolidated Current Assets of the Companies and the
Companies’ Subsidiaries, minus consolidated Current Liabilities of the Companies
and the Companies’ Subsidiaries, determined according to the accounting methods,
policies, practices and procedures, including classification and estimation
methodology, used by the Companies, the Companies’ Subsidiaries, and their
Affiliates in the preparation of the Financial Statements.
 
 
6

--------------------------------------------------------------------------------

 
“Objections Statement” means a statement setting forth in reasonable detail the
basis for the items on the Closing Statement being disputed in good faith.
 
“Permitted Liens” means (i) any restriction on transfer arising under any
applicable securities Laws, (ii) Liens in respect of Taxes or other governmental
charges not yet due and payable or the amount or validity of which is being
contested in good faith by appropriate proceedings by either Company and/or any
Company Subsidiary; (iii) Liens of landlords and mechanics’, carriers’,
workers’, repairers’, and similar Liens arising or incurred in the ordinary
course of business; (iv) zoning, entitlement, building, environmental and other
land use regulations imposed by Governmental Entities having jurisdiction over
any of the Leased Real Property which are not violated by the current use and
operation of the Leased Real Property; (v) covenants, conditions, restrictions,
easements and other similar matters of record or otherwise disclosed on title
surveys affecting any of the real property subject to the Real Property Leases
which do not materially impair the occupancy or use thereof for the purposes for
which it is currently used or proposed to be used by either Company and/or any
Company Subsidiary in connection with the Companies’ or the Companies’
Subsidiaries’ businesses; (vi) Liens arising under worker’s compensation,
unemployment insurance, social security, retirement and similar legislation;
(vii) purchase money Liens and Liens of lessors and licensors arising under
lease agreements or license arrangements; (viii) Liens granted to any lender at
or about the Closing in connection with any financing by Buyer or any of its
Affiliates for the transactions contemplated hereby.
 
“Person” means an association, a corporation, an individual, a partnership, a
limited liability company, a trust or any other entity or organization,
including a Governmental Entity.
 
“Pre-Closing Tax Periods” means all Tax periods ending on or before the Closing
Date and the portion through the end of the Closing Date for any Tax period that
includes but does not end on the Closing Date.
 
“Recoupment Indemnity Matter”  has the meaning set forth in Section 13.2.1(iv).
 
“Shareholder Approved Tax Matter” means (a) amending or otherwise changing any
Tax Return or Tax election of the Companies or the Companies’ Subsidiaries for a
Pre-Closing Tax Period or Straddle Period; (b) extending or waiving the
applicable statute of limitations with respect to a Tax of the Companies or the
Companies’ Subsidiaries for a Pre-Closing Tax Period or Straddle Period; (c)
filing any ruling request with any Governmental Entity that relates to Taxes or
Tax Returns of the Companies or the Companies’ Subsidiaries for a Pre-Closing
Tax Period or Straddle Period; or (d) any disclosure to, or discussions with,
any Governmental Entity regarding any Tax or Tax Returns of the Companies or the
Companies’ Subsidiaries for a Pre-Closing Tax Period or Straddle Period,
including disclosure to, or discussions with, a Governmental Entity with respect
to filing Tax Returns or paying Taxes for a Pre-Closing Tax Period (or Straddle
Period) in jurisdictions that the Companies or the Companies’ Subsidiaries did
not file a Tax Return (or pay Taxes) for such periods.
 
“Special Indemnity Matter” has the meaning set forth in Section 13.2.1(iv).
 
“Straddle Period” means any taxable period that includes, but does not end on,
the Closing Date.
 
 
7

--------------------------------------------------------------------------------

 
“Target Net Working Capital” means Eight Million Dollars ($8,000,000.00).
 
“Tax Benefit” shall mean any reduction in Taxes payable or any increase in any
Tax refund receivable (including any related interest).
 
“Tax Loss” means any (i) Tax of either Company and/or any Company Subsidiary for
a Pre-Closing Tax Period (or the portion of a Straddle Period ending on the
Closing Date determined as provided in Section 12.2.2) and (ii) any reasonable
fees and expenses of legal counsel or other tax advisors incurred by Buyer,
either Company and/or any Company Subsidiary in controlling a proceeding by any
Governmental Entity with respect to the Taxes set forth in clause
(i).  Notwithstanding the foregoing, Tax Losses shall exclude the following
Taxes (and related costs):  (a) Taxes to the extent reserved for as a Current
Liability on the Closing Statement, as finally determined; (b) Taxes directly
resulting from a breach by the Buyer of any covenant or other agreement in
Section 12.2; (c) the Buyer’s allocable share of any Transfer Taxes under
Section 12.2.4; and (d) Taxes resulting from a Buyer Closing Date Transaction.
 
“Tax Returns” means any return, report, statement, information return or other
document (including any related or supporting information) filed or required to
be filed with any Governmental Entity in connection with the determination,
assessment, collection or administration of any Taxes or the administration of
any Laws, regulations or administrative requirements relating to any Taxes,
including any schedule or attachment thereto, and including any amendment
thereof.
 
“Taxes” means any federal, state, local or foreign income, gross receipts,
license, payroll, employment, excise, severance, stamp, occupation, premium,
windfall profits, unclaimed property, environmental (including taxes under Code
§ 59A), customs duties, capital stock, franchise, profits, withholding, social
security (or similar), unemployment, disability, real property, personal
property, sales, use, transfer, registration, value added, alternative or add-on
minimum, estimated, or other taxes, charges, fees imposts, levies of any kind
whatsoever, including any interest, penalty or addition thereto, whether
disputed or not.
 
“Trade Secret” means, in addition to any information solely applicable to the
Companies and the Companies’ Subsidiaries which is covered by any definition of
“trade secret” or any equivalent term under state, local or federal law, all
information solely applicable to the Companies and the Companies’ Subsidiaries,
without regard to form, including, but not limited to, technical or nontechnical
data, a formula, a pattern, a compilation, a program, a device, a method, a
technique, a drawing, a process, financial data, financial plans, product plans,
distribution lists, a list of actual or potential customers, or a list of actual
or potential contractors, consultants and suppliers, which is not commonly known
by or available to the public and which information: (i) derives economic value,
actual or potential, from not being generally known to, and not being readily
ascertainable by proper means by, other persons who can obtain economic value
from its disclosure or use; and (ii) is the subject of efforts that are
reasonable under the circumstances to maintain its secrecy.  “Trade Secret”
shall not include information that has become generally available to the public
by the act of one who has the right to disclose such information without
violating any right or privilege of Buyer, and shall not include information
which may also pertain to the Shareholder or its Affiliates (other than the
Companies and the Companies’ Subsidiaries).  Nothing in this Agreement is
intended, or shall be construed, to limit the protections of the Uniform Trade
Secrets Act of any state or any other applicable law protecting trade secrets or
other confidential information.
 
 
8

--------------------------------------------------------------------------------

 
1.2 Other Defined Terms. The following terms have the meanings defined for such
terms in the locations set forth below:
 
Term
Location
Additional Cap
Section 13.2.2
Agreement
Introductory Paragraph
Allocation Schedule
Section 12.2.1(iii)(E)
BioScrip Obligation(s)
Section 15.12
Buyer
Introductory Paragraph
Buyer Indemnified Parties
Section 13.2.1
Closing
Article 3
Closing Date
Article 3
Closing Statement
Section 4.2
Companies
Introductory Paragraph
Comparable Benefits
Section 11.5
Confidentiality Agreement
Section 11.4
Deductible
Section 13.2.2
Effective Date
Introductory Paragraph
Effective Time
Article 3
Employees
Section 12.4.3(ii)
Estimated Closing Date Net Working Capital
Section 4.2
EVPA
Introductory Paragraph
EVPA Shares
Section 5.4.1
Excess Losses
Section 13.2.2(iii)
Final Closing Date Net Working Capital
Section 4.2
Financial Statements
Section 5.5
Fundamental Representations
Section 13.1
General Cap
Section 13.2.2
Government Programs
Section 5.20.1
Health Care Laws
Section 5.23.1
HIPAA
Section 5.23.1
Holding Newco
Recitals
Indemnification Notice
Section 13.6
Indemnitee
Section 13.6
Indemnitor
Section 13.6
Labor Laws
Section 5.18.2
Latest Balance Sheets
Section 5.5
Leased Real Property
Section 5.8.1
LHC
Introductory Paragraph
Material Contracts
Section 5.10.2
LHC Obligation
Section 15.13
Necessary Consents and Approvals
Section 8.7
New Plans
Section 11.5
Old Plans
Section 11.5
Operating Newcos
Recitals
Private Programs
Section 5.20.1

 
 
9

--------------------------------------------------------------------------------

 
Term
Location
Providers
Section 12.4.3(ii)
Purchase Price
Section 4.1
Real Property Leases
Section 5.8.1
Restricted Territory
Section 12.4.2
Section 338(h)(10) Election
Section 12.2.1(iii)(E)
Seller Party
Section 10.5
Shareholder
Introductory Paragraph
Shareholder Indemnified Parties
Section 13.4.1
Shareholder Prepared Returns
Section 12.2.1
Shares
Recitals
SMHH
Introductory Paragraph
SMHH Shares
Section 5.4.1
Stark Law
Section 5.23.1
Survival Period
Section 13.1
Tax Contest
Section 12.2.5(i)
Third Party Claim
Section 13.6
Top Suppliers
Section 5.25
Transfer Taxes
Section 12.2.4
WARN Act
Section 5.18.4
   

 
ARTICLE 2
SALE AND PURCHASE OF SHARES
 
Subject to the terms and the conditions set forth in this Agreement and on the
basis of the representations and warranties herein, Shareholder agrees to sell,
convey, transfer, assign and deliver to Buyer and Buyer agrees to purchase,
receive and accept from Shareholder all of the Shares, free and clear of all
Liens.
 
ARTICLE 3
CLOSING
 
Unless the parties hereto otherwise agree in writing, the actions contemplated
to consummate the transactions under this Agreement (the “Closing”) shall take
place on the later of March 31, 2014 or the second business day following the
satisfaction or waiver of all conditions to the obligations of the parties to
consummate the transactions contemplated hereby (other than conditions with
respect to actions the respective parties will take at the Closing itself) (the
“Closing Date”). The Closing shall occur at a time and place mutually determined
by the parties, and shall be deemed effective at 12:01 a.m. Eastern Time on the
date immediately following the Closing Date (the “Effective Time”).
 
ARTICLE 4
PURCHASE PRICE
 
4.1 Purchase Price. The amount payable in consideration for the sale by the
Shareholder of the Shares (the “Purchase Price”) shall be equal to (a) SIXTY
MILLION Dollars ($60,000,000.00), less (b) One Dollar ($1.00) for each dollar
that the Closing Date Net Working Capital is less than the Target Net Working
Capital, plus (c) One Dollar ($1.00) for each dollar that the Closing Date Net
Working Capital is more than the Target Net Working Capital. The Purchase Price
shall be paid as set forth in this Article 4.
 
 
10

--------------------------------------------------------------------------------

 
4.2 Payment and Adjustment of Purchase Price. At least five (5) days prior to
the Closing Date, the Shareholder shall deliver to Buyer a certificate signed by
the chief financial officer of Shareholder (or person with similar
responsibilities) setting forth the Shareholder’s estimate of the Closing Date
Net Working Capital (the “Estimated Closing Date Net Working Capital”). At the
Closing, Buyer shall pay to Shareholder an amount equal to the Purchase Price
(based on the Estimated Closing Date Net Working Capital) in readily available
funds via wire transfer to an account designated by Shareholder.  Within
forty-five (45) days after the Closing Date, Buyer will deliver to Shareholder a
reasonably detailed proposed statement of the final calculation of Closing Date
Net Working Capital (collectively, the “Closing Statement”). After delivery of
the Closing Statement, Buyer and the Companies shall promptly make available to
Shareholder the working papers, books, records and personnel of the Companies
and their accountants that the Shareholder reasonably requires in order to
review and understand the Closing Statement and the basis therefor. Shareholder
may make inquiries of Buyer or the Companies and their accountants and
appropriate employees regarding questions concerning or disagreements with the
proposed Closing Statement arising in the course of Shareholder’s review
thereof, and Buyer and the Companies shall cause any such employees and
accountants to reasonably cooperate with and respond to such inquiries in a
prompt manner. If Shareholder has any objections to the Closing Statement,
Shareholder shall deliver to Buyer an Objections Statement within thirty (30)
days after delivery of the Closing Statement. If an Objections Statement is not
delivered to Buyer within thirty (30) days after delivery of the Closing
Statement, the Closing Statement shall be final, binding and non-appealable by
the parties hereto. Shareholder hereby waives the right to assert any objection,
other than allegations of fraud, with respect to the Closing Statement that is
not asserted in an Objections Statement delivered to Buyer within thirty (30)
days after delivery of the Closing Statement. If Shareholder timely delivers an
Objection Statement, Shareholder and Buyer shall negotiate in good faith to
resolve any identified objections. If they do not reach a final resolution
within fifteen (15) days after the delivery of the Objections Statement,
Shareholder or Buyer may, with written notice to the other party, submit such
Dispute to the Independent Auditor. Shareholder and Buyer shall use their
commercially reasonable efforts to cause the Independent Auditor to resolve all
disagreements as soon as practicable. The Closing Statement reflecting the
resolution of the Dispute by the Independent Auditor shall be final, binding and
non-appealable on the parties hereto. “Final Closing Date Net Working Capital”
means the final, binding and non-appealable determination of the Closing Date
Net Working Capital pursuant to this Section 4.2.  The Shareholder shall pay a
portion of the fees and expenses of the Independent Auditor, if any, equal to
100% of such fees and expenses multiplied by a fraction, the numerator of which
is equal to the difference between Buyer’s proposed Closing Date Net Working
Capital as adjusted after taking into account the items Shareholder disputes in
good faith and the Independent Auditor’s determination, and the denominator of
which is equal to the difference between Buyer’s proposed Closing Date Net
Working Capital as adjusted after taking into account the items Shareholder
disputes in good faith and Buyer’s proposed Closing Date Net Working Capital.
Buyer shall pay that portion of the fees and expenses of the Independent Auditor
that Shareholder is not required to pay hereunder. If the amount required to be
paid as the Purchase Price based on the Final Closing Date Net Working Capital
is greater than the amount paid to Shareholder on the Closing Date, Buyer shall
pay to Shareholder the amount of such excess in readily available funds via wire
transfer to an account designated by Shareholder. If the amount required to be
paid as the Purchase Price based on the Final Closing Date Net Working Capital
is less than the amount paid to Shareholder on the Closing Date, Shareholder
shall pay the amount of such shortfall to Buyer in readily available funds via
wire transfer to an account designated by Buyer. Any payment required under this
Section shall be (A) due within five (5) business days of determination of the
Final Closing Date Net Working Capital; and (B) paid by wire transfer of
immediately available funds to such account as is directed by Buyer or
Shareholder, as the case may be.
 
 
11

--------------------------------------------------------------------------------

 
ARTICLE 5
REPRESENTATIONS AND WARRANTIES RELATING TO THE COMPANIES
 
The Shareholder and the Companies, jointly and severally, represent and warrant
to Buyer that, as of the date hereof and at the Closing Date:
 
5.1 Organization and Corporate Power. Each of the Companies and the Companies’
Subsidiaries (a) is a corporation or other legal entity duly organized, validly
existing and in good standing under the Laws of its jurisdiction of
organization, (b) has all requisite power to own and operate its properties and
to carry on its businesses as now conducted and (c) is, where applicable, duly
qualified to do business and is, where applicable, in good standing in every
jurisdiction in which its ownership of property or the conduct of its business
as now conducted requires it to qualify, except, in each case, where the failure
to be so qualified or in good standing would not have a Material Adverse Effect.
The Companies have made available to Buyer copies of the applicable certificate
of incorporation, bylaws or other charter or organizational documents of each of
the Companies and Companies’ Subsidiaries as currently in effect. Except for the
Companies’ equity ownership interests of the Companies’ Subsidiaries, none of
the Companies or any of the Companies’ Subsidiaries own any capital stock,
partnership interest or other equity ownership interest in any other Person.
 
5.2 Authorization; Valid and Binding Agreement. The Companies have full
corporate power and authority to execute and deliver this Agreement and to
perform its obligations hereunder. The execution and delivery of this Agreement
by the Companies and the consummation by the Companies of the transactions
contemplated hereby have been duly authorized by all necessary corporate
(including shareholder/member authorization to the extent necessary) action and
no other corporate (including shareholder/member) proceedings on the part of the
Companies are necessary to authorize this Agreement and the transactions
contemplated hereby. This Agreement constitutes the valid and legally binding
obligations of the Companies, enforceable in accordance with its terms and
conditions, subject to Laws of general application relating to public policy,
bankruptcy, insolvency and the relief of debtors and rules of Law governing
specific performance, injunctive relief and other equitable remedies.
 
5.3 No Breach. Except as set forth on Schedule 5.3, the execution, delivery and
performance of this Agreement by the Companies and the consummation of the
transactions contemplated hereby by the Companies does and will not (i) result
in any breach of, constitute a default under or result in a violation of the
provisions of the Companies’ or any Companies’ Subsidiaries’ certificate of
incorporation, bylaws or other charter or organizational documents, (ii)
conflict with, result in a breach of, constitute a default under, result in the
acceleration of, create in any party the right to accelerate, terminate, modify,
or cancel, or require any notice or consent under any Material Contract or Real
Property Lease, (iii) result in the imposition or creation of a Lien upon or
with respect to any of the Shares, (iv) violate any applicable Law, order,
judgment or decree to which the Companies or any Companies’ Subsidiaries is
subject or (v) require the Companies or any Companies’ Subsidiaries to obtain
any authorization, consent or approval of or require the Companies or any
Companies’ Subsidiaries to provide any notice to or make any filing with any
Governmental Entity under the provisions of any applicable material Law, order,
judgment or decree to which the Companies or any Companies’ Subsidiaries is
subject.
 
 
12

--------------------------------------------------------------------------------

 
5.4 Capitalization.
 
5.4.1 The entire authorized equity securities of EVPA consist of 200,000 shares
of common stock, no par value per share, of which 118,541.96 shares are issued
and outstanding (the “EVPA Shares”).  The entire authorized equity securities of
SMHH consist of 5,000 shares of common stock, par value $1.00 per share, of
which 1,000 shares are issued and outstanding (the “SMHH Shares”). The EVPA
Shares, the SMHH Shares, and upon Closing, the membership interests of the
Holding Newcos, constitute all of the Shares.  Shareholder is the sole owner (of
record and beneficially) of all of the Shares, free and clear of all Liens,
except for (i) Liens described in subsections (i) and (viii) of the definition
of Permitted Liens, and/or (ii) Liens that will be terminated or released at the
Closing, which Liens are set forth on Schedule 5.7. Upon termination or release
at the Closing of those Liens set forth on Schedule 5.7, there will be no
restrictions on the right of the Shareholder to transfer the Shares to Buyer
pursuant to this Agreement.  The assignments, endorsements, stock powers, or
other instruments of transfer to be delivered by Shareholder to Buyer at the
Closing will be sufficient to transfer Shareholder’s entire interest in the
Shares (of record and beneficially) owned by Shareholder.  Upon transfer to
Buyer of the certificates representing the Shares, Buyer will receive good title
to the Shares, free and clear of all Liens. To the Company’s knowledge, no third
party has asserted a claim of ownership to any of the Shares since March 25,
2010.
 
5.4.2 All of the Shares have been duly authorized, are validly issued, fully
paid and non-assessable. There are no outstanding or authorized options,
warrants, purchase rights, subscription rights, conversion rights, exchange
rights, or other contracts or commitments that could require the Companies to
issue, sell or otherwise cause to become outstanding any of their capital stock.
There are no outstanding or authorized stock appreciation, phantom stock, profit
participation, or similar rights with respect to the Companies.
 
5.4.3 All of the issued and outstanding shares of capital stock or other equity
ownership interests of the Companies’ Subsidiaries are duly authorized and
validly issued, fully paid and, to the extent applicable, non-assessable. All of
the issued and outstanding shares of capital stock or other equity ownership
interests of the Companies’ Subsidiaries are owned by the Companies, free and
clear of all Liens, except for (i) Liens described in subsections (i) and (viii)
of the definition of Permitted Liens, and/or (ii) Liens that will be terminated
or released at the Closing, which Liens are set forth on Schedule 5.7. There are
no outstanding or authorized options, warrants, purchase rights, subscription
rights, conversion rights, exchange rights, or other contracts or commitments
that could require any Companies’ Subsidiaries to issue, sell or otherwise cause
to become outstanding any of its capital stock or other equity ownership
interests.  Schedule 5.4.3 lists for each of the Companies’ Subsidiaries, its
authorized equity securities, the number and type of equity securities issued
and outstanding, and the Company holder of such securities and the number of
securities of each entity held by the applicable Company.  There are no
outstanding or authorized stock appreciation, phantom stock, profit
participation, or similar rights with respect to the Companies’ Subsidiaries. As
of the Effective Time, the Companies will hold, beneficially and of record, good
title to all capital stock or other equity ownership interests of the Companies’
Subsidiaries, free and clear of all Liens. To the Company’s knowledge, no third
party has asserted a claim of ownership to any of the issued and outstanding
shares of capital stock or other equity ownership interests of the Companies’
Subsidiaries since March 25, 2010.
 
 
13

--------------------------------------------------------------------------------

 
5.4.4 None of the Companies nor the Companies’ Subsidiaries owns, or is a party
to or is bound by any contract or commitment to acquire, any equity security or
other security of any Person or any direct or indirect equity or ownership
interest in any other business.  None of the Companies nor the Companies’
Subsidiaries is obligated to provide funds to or make any investment (whether in
the form of a loan, capital contribution, or otherwise) in any other Person.
 
5.5 Financial Statements. The Companies have furnished Buyer with copies of the
following (collectively, the “Financial Statements”):
 
5.5.1 the unaudited consolidated balance sheet of the Companies and the
Companies’ Subsidiaries as of December 31, 2011, 2012 and 2013 (which does not
include the home health businesses operated through Infusion Therapy
Specialists, Inc., Scott-Wilson, Inc., and Option Health, Ltd.);
 
5.5.2 the unaudited pro forma selected balance sheet accounts reflecting the
assets and liabilities of the home health businesses operated through Infusion
Therapy Specialists, Inc., Scott-Wilson, Inc., and Option Health, Ltd. as of
December 31, 2013 (collectively with the balance sheet provided under subsection
5.5.1 above, the “Latest Balance Sheets”); and
 
5.5.3 the unaudited consolidated statement of income of the Companies and the
Companies’ Subsidiaries, and for the home health businesses operated through
Infusion Therapy Specialists, Inc., Scott-Wilson, Inc., and Option Health, Ltd.
for the years ended December 31, 2011, 2012 and 2013.
 
The balance sheets provided under subsections 5.5.1 above have been prepared
consistent with past practices, except as set forth therein or on Schedule 5.5.
The balance sheet provided under subsection 5.5.2 above and the statements of
income provided under subsections 5.5.3 above have been prepared consistent with
accounting methods used in the past with respect to the Companies and the
Companies’ Subsidiaries, except as set forth therein or on Schedule 5.5. The
Financial Statements are true, correct and complete in all material respects,
and, except as set forth therein or on Schedule 5.5 , have been prepared using
consistent accounting practices for the periods and dates presented.  The
Financial Statements present fairly in all material respects the financial
position of the Company and the Companies’ Subsidiaries, as applicable, as of
the dates indicated and present fairly in all material respects the results of
the operations, changes in equity and cash flows for the periods then
ended.  The Financial Statements have been prepared in accordance with the books
and records of the Company and the Companies’ Subsidiaries, as applicable, which
have been properly maintained and are true, complete and correct in all material
respects.  Neither the Company nor the Companies’ Subsidiaries has received any
advice or notification that it has used any improper accounting practice that
would have the effect of not reflecting or incorrectly reflecting in the
Financial Statements or the books and records, any properties, assets,
liabilities, revenues or expenses.
 
 
14

--------------------------------------------------------------------------------

 
5.6 Absence of Certain Developments. Since the date of the Latest Balance
Sheets, there has not been any Material Adverse Effect. Since the date of the
Latest Balance Sheets, except (i) as set forth on Schedule 5.6, and (ii) as
contemplated by this Agreement, the business of the Companies and the Companies’
Subsidiaries have been operated in all material respects in the ordinary course
of business consistent with past practice, and the Companies and each Companies’
Subsidiary has complied in all material respects with the covenants and
restrictions set forth in Section 10.1.1 (other than Section 10.1.1(v), (vi) and
(ix)) and Section 10.1.2 (other than Section 10.1.2(v)) hereof.
 
5.7 Title to Properties. Except as set forth on Schedule 5.7, the Companies and
the Companies’ Subsidiaries have good title to all of the tangible personal
property shown to be owned by them on the Latest Balance Sheets (except for such
personal property sold or disposed of subsequent to the date thereof in the
ordinary course of business), free and clear of all Liens, except for Permitted
Liens and those Liens set forth on Schedule 5.7.  All items of tangible personal
property (including inventory) shown to be owned by the Companies and each
Companies’ Subsidiaries on the Latest Balance Sheets (except for such personal
property sold or disposed of subsequent to the date thereof in the ordinary
course of business) are in the aggregate in adequate operating condition and
repair, normal wear and tear excepted, other than machinery and equipment under
repair or out of service in the ordinary course of business, and are of a
quality and quantity usable and, with respect to inventory, saleable in the
ordinary course of business.
 
5.8 Real Property.
 
5.8.1 Leased Real Property. The real property demised by the leases described on
Schedule 5.8.1 (the “Real Property Leases”) constitutes all of the real property
leased by the Companies and each Companies’ Subsidiaries (the “Leased Real
Property”). With respect to each Real Property Lease, except as set forth on
Schedule 5.8.1, neither the Companies, any Companies’ Subsidiaries nor, to the
Companies’ knowledge, any of the other counterparties thereto is in material
breach or material default under any such Real Property Lease.  Each of the
Companies and each of the Companies’ Subsidiaries has a valid leasehold interest
in its Leased Real Property free and clear of any Liens other than Permitted
Liens.  Each of the Real Property Leases is in full force and effect in all
material respects.  None of the Companies nor any of the Companies’ Subsidiaries
has received any written notice within the past twenty-four (24) months of any
pending or threatened condemnations, planned public improvements, annexation,
special assessments, zoning or subdivision changes, or other adverse claims
affecting the Leased Real Property.  All licenses, permits and approvals
required for the occupancy and operation of the Leased Real Property as
presently being used have been obtained and are in full force and effect and
none of the Companies or any of the Companies’ Subsidiaries has received any
written notice of violations in connection with such items.  Except as set forth
on Schedule 5.8.1, none of the Companies nor any of the Companies’ Subsidiaries
has subleased, licensed or otherwise granted anyone the right to use or occupy
the Leased Real Property or any portion thereof or collaterally assigned or
granted any other security interest in any such lease or interest therein.
 
 
15

--------------------------------------------------------------------------------

 
5.8.2 Owned Real Property. Neither the Companies nor any Companies’ Subsidiaries
owns any real property.
 
5.9 Tax Matters. Except as set forth on Schedule 5.9:
 
5.9.1 Each of the Companies and the Companies’ Subsidiaries has timely filed all
material Tax Returns in all jurisdictions in which Tax Returns are required to
be filed, and such Tax Returns are correct and complete in all material
respects.  None of the Companies nor any of the Companies’ Subsidiaries is the
beneficiary of any extension of time within which to file any Tax Return.  All
Taxes of, or for which there exists liability of, the Companies and the
Companies’ Subsidiaries (whether or not shown on any Tax Return) have been fully
and timely paid.  There are no Liens for any Taxes (other than a Lien for
current real property or ad valorem Taxes not yet due and payable) on any of the
assets of the Companies or the Companies’ Subsidiaries.  No claim has ever been
made by any Governmental Entity in a jurisdiction where the  Companies or any of
the Companies’ Subsidiaries does not file a Tax Return that such entity may be
subject to Taxes in that jurisdiction.
 
5.9.2 None of the Companies nor any of the Companies’ Subsidiaries has received
any written notice of assessment or proposed assessment in connection with any
Taxes, and to the knowledge of the Company and the Companies’ Subsidiaries there
are no threatened or pending disputes, claims, audits or examinations regarding
any Taxes or the assets of the Companies or any of the Companies’
Subsidiaries.  Neither the Companies nor any of the Companies’ Subsidiaries has
waived any statute of limitations in respect of any Taxes or agreed to a Tax
assessment or deficiency.
 
5.9.3 Each of the Companies and the Companies’ Subsidiaries has materially
complied with all applicable laws, rules and regulations relating to the
withholding of Taxes and the payment thereof to appropriate Governmental
Entities, including Taxes required to have been withheld and paid in connection
with amounts paid or owing to any employee or independent contractor, and Taxes
required to be withheld and paid pursuant to Code Sections 1441 and 1442 or
similar provisions under foreign law.
 
5.9.4 The unpaid Taxes of each of the Companies and the Companies’ Subsidiaries
(i) did not, as of the most recent fiscal month end, exceed the reserve for Tax
Liability (rather than any reserve for deferred Taxes established to reflect
timing differences between book and Tax income) set forth on the Latest Balance
Sheets, (ii) do not exceed that reserve as adjusted for the passage of time
through the Closing Date in accordance with past custom and practice of the
Companies and the Companies’ Subsidiaries in filing their Tax Returns and (iii)
do not exceed the amount reflected as a Current Liability in the computation of
Net Working Capital.
 
5.9.5 Except as set forth on Schedule 5.9.5, none of the Companies nor any of
the Companies’ Subsidiaries is a party to any Tax allocation or Tax sharing
agreement and none of the Companies nor any of the Companies’ Subsidiaries has
been a member of an affiliated group within the meaning of Section 1504(a) of
the Code filing a consolidated federal income Tax Return (other than a group the
common parent of which is BioScrip, Inc.) or has any Tax Liability of any Person
under Treasury Regulation Section 1.1502-6 or any similar provision of state,
local or foreign law, or as a transferee or successor, by contract or otherwise.
 
 
16

--------------------------------------------------------------------------------

 
5.9.6 Each of the Companies and the Companies’ Subsidiaries has disclosed on its
federal income Tax Returns all positions taken thereon that could reasonably
give rise to a substantial understatement of federal income Tax within the
meaning of Code Section 6662.
 
5.9.7 None of the Companies nor any of the Companies’ Subsidiaries has
participated in any reportable transaction, as defined in Code Section
6707A(c)(1) and Regulation Section 1.6011-4(b)(1), or a transaction
substantially similar to a reportable transaction.
 
5.9.8 None of the Companies nor any of the Companies’ Subsidiaries has
distributed stock of another entity, or had its stock distributed by another
entity in a transaction governed or intended to be governed by Section 355 or
Section 361 of the Code.
 
5.9.9 Neither of the Companies nor any Company Subsidiary is a party to any
agreement, contract, arrangement or a plan that has resulted or could reasonably
result, separately or in the aggregate, in a payment of (i) any “excess
parachute payment within the meaning of Section 280G of the Code (or any
corresponding provision of state, local or foreign law) or (ii) any amount that
will not be fully deductible as a result of Section 162(m) of the Code (or any
corresponding provision of state, local, or foreign law).
 
5.9.10 Neither of the Companies nor any Company Subsidiary will be required to
include any item of income in, or exclude any item of deduction from, taxable
income for any taxable period (or portion thereof) ending after the Closing Date
as a result of any:
 
(i) change in method of accounting for a taxable period ending on or prior to
the Closing Date;
 
(ii) use of an improper method of accounting for a taxable period ending on or
prior to the Closing Date;
 
(iii) "closing agreement" as described in Section 7121 of the Code (or any
corresponding or similar provision of state, local or non-U.S. income Tax law)
executed on or prior to the Closing Date;
 
(iv) intercompany transaction or excess loss account described in Treasury
Regulations under Section 1502 of the Code (or any corresponding or similar
provision of state, local, or non-U.S. income Tax law);
 
(v) installment sale or open transaction disposition made on or prior to the
Closing Date;
 
(vi) prepaid amount received on or prior to the Closing Date; or
 
(vii) election under Section 108(i) of the Code.
 
 
17

--------------------------------------------------------------------------------

 
5.9.11 The Companies and each Company Subsidiary that is a corporation are
members of the federal consolidated group of which BioScrip is the common parent
and each Company Subsidiary that is a limited liability company is a disregarded
entity for federal tax purposes.
 
5.10 Contracts and Commitments.
 
5.10.1 Schedule 5.10.1 lists all of the following contracts, agreements,
arrangements, commitments, obligations and plans (whether written or oral,
unless otherwise specified below) to which any of the Companies or any of
Companies’ Subsidiaries is a party:
 
(i) Any pension, retirement or deferred compensation plan or contract or other
bonus plan, other than as described in Schedule 5.13;
 
(ii) Any collective bargaining agreement or contract with any labor union;
 
(iii) Any employment agreement for the employment of any Person;
 
(iv) Any engagement of any medical director or any physician as a consultant,
independent contractor or agent;
 
(v) Any loan agreement or indenture with any third party relating to
Indebtedness under which the Companies or any Companies’ Subsidiaries has
borrowed money or made any loan;
 
(vi) Any lease agreement with any third party under which the Companies or any
Companies’ Subsidiaries is lessee of any personal property owned by any third
party for which the annual rental payments paid by the Companies or any
Companies’ Subsidiaries (as applicable) exceeds $25,000 and which is not
terminable on thirty (30) or fewer days’ notice by the Companies or any
Companies’ Subsidiaries without Liability for any material penalty;
 
(vii) Any lease agreement under which the Companies or any Companies’
Subsidiaries is lessor of any personal property owned by the Companies or any
Companies’ Subsidiaries for which the annual rental payments paid to the
Companies or any Companies’ Subsidiaries (as applicable) exceeds $25,000 and
which is not terminable by on thirty (30) or fewer days’ notice by the Companies
or any Companies’ Subsidiaries without Liability for any material penalty;
 
(viii) Any contract or agreement (other than those covered by clauses (i)
through (vi) above and other than the Real Property Leases) with any third party
involving annual payments to or by the Companies or any Companies’ Subsidiaries
of more than $50,000 with respect to any such contract or agreement;
 
(ix) Any partnership or joint venture contract;
 
(x) Any profit sharing, stock option, stock purchase, stock appreciation,
deferred compensation, severance, or other material plan or arrangement for the
benefit of the Companies’ or the Companies’ Subsidiaries’ current or former
directors, officers, and employees not otherwise listed on Schedule 5.13;
 
 
18

--------------------------------------------------------------------------------

 
(xi) Any written agreement between any of the Companies or the Companies’
Subsidiaries and any of their Affiliates pursuant to which amounts are payable
by or to the Companies or the Companies’ Subsidiaries;
 
(xii) Any contract with any third party containing covenants prohibiting the
Companies or any Companies’ Subsidiaries in any material respect following the
Closing from: (a) competing in any line of business, (b) soliciting employees or
businesses, or (c) disclosing information (other than contracts entered into in
the ordinary course of business); and
 
(xiii)           Any contract subject to Executive Order 11246.
 
5.10.2 With respect to each of the contracts, agreements and plans set forth on
Schedule 5.10.1 (each a “Material Contract”), except as set forth on Schedule
5.10.2, (i) the Companies have made available to Buyer a copy of such Material
Contract, (ii) neither the Companies, any Companies’ Subsidiaries nor, to the
Companies’ knowledge, any other party thereto, is in material breach of such
Material Contract or default under any such Material Contract, and (iii) each
such Material Contract is valid and in full force in effect in all material
respects and constitutes a legal, valid and binding obligation of the Companies
or the applicable Companies’ Subsidiaries and, to the Companies’ knowledge, the
other parties thereto, and is enforceable against the Companies or the
applicable Companies’ Subsidiaries in accordance with its terms, subject to
applicable bankruptcy, insolvency, reorganization, moratorium and similar Laws
affecting creditors’ rights generally, and subject, as to enforceability, to
general principles of equity (regardless of whether enforcement is sought in a
proceeding at Law or in equity).
 
5.11 Intellectual Property.
 
5.11.1 Schedule 5.11 contains a list of all of the Intellectual Property, and
all applications for the registration of any Intellectual Property, that are
material to (and used in the conduct of) the businesses of the Companies and
each Companies’ Subsidiaries and that are owned, licensed or filed by the
Companies and any Companies’ Subsidiaries. Except as set forth on Schedule 5.11:
(i) since January 1, 2012, neither the Companies nor any Companies’ Subsidiaries
has received any written notices of infringement or misappropriation from any
third party with respect to the use by the Companies and any Companies’
Subsidiaries of any material Intellectual Property owned or used by the
Companies or any Companies’ Subsidiaries during such period; (ii) to the
Companies’ knowledge, no third party is materially infringing or
misappropriating any Intellectual Property owned by the Companies or any
Companies’ Subsidiaries, and (iii) the trademarks, service marks, and trade
names identified on Schedule 5.11 are owned by the Companies or the Companies’
Subsidiaries, were first used in commerce by the Companies or any Companies’
Subsidiaries as of the date set forth on Schedule 5.11, and have been
continuously and properly used since the identified first use date. All
Intellectual Property owned by the Companies or the Companies’ Subsidiaries is
owned free and clear of all Liens.  The Companies and the Companies’
Subsidiaries own or have the right to use all of the Intellectual Property used
in the conduct of their businesses.
 
 
19

--------------------------------------------------------------------------------

 
5.11.2 The Companies and Companies’ Subsidiaries have obtained and possesses
valid licenses, sublicenses or other rights to legally use all of the software
programs present on the computers and other software-enabled electronic devices
that it owns or leases or that it has otherwise provided to its employees for
their use in connection with each Company’s business.
 
5.12 Litigation. Except as set forth on Schedule 5.12, there are no actions,
suits, hearings,  or proceedings currently pending or, to the Companies’
knowledge, threatened against the Companies or any Companies’ Subsidiaries, at
Law or in equity, before or by any Governmental Entity, and neither the
Companies nor any Companies’ Subsidiaries is subject to any outstanding
judgment, injunction, order, ruling or decree of any Governmental Entity with
respect to which the Companies or any Companies’ Subsidiaries has any future
material obligations.
 
5.13 Employee Benefit Plans.
 
5.13.1 Schedule 5.13 sets forth a list of each Employee Benefit Plan maintained
by the Companies and the Companies’ Subsidiaries or to which the Companies and
any Companies’ Subsidiaries are obligated to contribute.
 
5.13.2 Except as set forth on Schedule 5.13:
 
(i) All such Employee Benefit Plans have been made available to Buyer and/or its
agents;
 
(ii) Each such Employee Benefit Plan has been maintained, funded and
administered in material compliance with its terms and all applicable Laws
(including, to the extent applicable, the applicable requirements of the
Employee Retirement Income Security Act of 1974, as amended (“ERISA”), and the
Code), except as would not result in a material Loss to the Companies and the
Companies’ Subsidiaries;
 
(iii) Other than routine claims for benefits, there is no claim or lawsuit
pending or, to the knowledge of the Companies, overtly threatened against the
Companies or the Companies’ Subsidiaries arising out of any such Employee
Benefit Plan, except for any such claim or lawsuit as would not result in a
material Loss to the Companies or the Companies’ Subsidiaries;
 
(iv) Each such Employee Benefit Plan that is intended to meet the requirements
of a “qualified plan” under Section 401(a) of the Code has received a favorable
determination letter or prototype opinion letter from the Internal Revenue
Service, and, to the Companies’ knowledge, nothing has occurred that would be
reasonably likely to cause the loss of such qualified status of such plan(s);
 
(v) No such Employee Benefit Plan is a defined benefit pension plan or “multiple
employer welfare arrangement” under Section 3(40) of ERISA or has, since
December 31, 2008, been subject to the minimum funding requirements of Section
412 of the Code or Title IV of ERISA; and
 
 
20

--------------------------------------------------------------------------------

 
(vi) Neither the Companies nor any Companies’ Subsidiaries have ever contributed
to, or had any obligation to contribute to, any “multiemployer plan” under
Section 3(37) of ERISA.
 
5.13.3 This Section 5.13 constitutes the sole and exclusive representations and
warranties of the Companies and the Companies’ Subsidiaries with respect to any
matters relating to any Employee Benefit Plan.
 
5.14 Insurance. Since January 1, 2009, there have been maintained by or on
behalf of the Companies and the Companies’ Subsidiaries (i) general and
professional liability insurance coverage , and (ii) various policies and forms
of insurance insuring the business of the Companies and the Companies’
Subsidiaries, which are, in each case, of the type and in amounts customary and
adequate for the businesses then conducted by the Companies and the Companies’
Subsidiaries.  Schedule 5.14 lists all insurance policies to which any of the
Companies or any of the Companies’ Subsidiaries is a party, an insured, or a
beneficiary, or under which any director, officer, or manager of any of the
Companies or any of the Companies’ Subsidiaries, in his or her capacity as such,
is covered. All such policies are maintained on an occurrence basis, except as
disclosed on Schedule 5.14. Except as provided on Schedule 5.14, none of such
insurance policies provide for any retrospective premium adjustments on the part
of the Companies or Companies’ Subsidiaries. All such insurance policies are in
full force and effect. Neither the Companies nor any Companies’ Subsidiaries is
in default regarding the policies of any such insurance, including, without
limitation, failure to make timely payments of all premiums due thereon, and
they have not failed to file any notice or present any claim thereunder in due
and timely fashion.  No insured under any such insurance policy has, and to
Company’s knowledge, no insurer has, repudiated any material provision
thereof.  Copies of all insurance policies set forth on Schedule 5.14 have been
delivered to Buyer.
 
5.15 Compliance with Laws. Except as set forth on Schedule 5.15, the Companies
and the Companies’ Subsidiaries are in material compliance with all Laws,
orders, judgments, decrees or any other requirement of any Governmental Entity
applicable to the Companies or the Companies’ Subsidiaries.
 
5.16 Environmental Matters. Except as set forth on Schedule 5.16:
 
5.16.1 The Companies and the Companies’ Subsidiaries are in compliance with all
applicable Environmental Laws, except where the failure to obtain or comply
would not have a Material Adverse Effect. The Companies and the Companies’
Subsidiaries possess all material permits, registrations, licenses and other
authorizations required under applicable Environmental Laws to be possessed by
them with respect to the conduct of their respective businesses as presently
conducted, and are in compliance with such permits, registrations, licenses and
authorizations, except where the failure to obtain or comply would not have a
Material Adverse Effect.
 
5.16.2 Neither the Companies nor the Companies’ Subsidiaries has, since January
1, 2012, received any written notice from any Governmental Entity that alleges
that the Companies or any Companies’ Subsidiaries is in material violation of
any Environmental Law or has any Liability arising under applicable
Environmental Laws relating to either the Companies, the Companies’ Subsidiaries
or their facilities.
 
 
21

--------------------------------------------------------------------------------

 
5.16.3 This Section 5.16 constitutes the sole and exclusive representations and
warranties of the Companies and the Companies’ Subsidiaries with respect to any
environmental matters, including, without limitation, any arising under
Environmental Laws.
 
5.17 Related Party Transactions. Except as (i) set forth on Schedule 5.17 or
(ii) reflected in the Financial Statements, none of the Shareholder, nor any of
the officers, directors, employees, or managers of the Shareholder, the
Companies or the Companies’ Subsidiaries has entered into any outstanding
agreement or contract with the Companies or any Companies’ Subsidiaries.
 
5.18 Employees.
 
5.18.1 Schedule 5.18.1(i) sets forth a list, on a de-identified basis, of all
employees of the Companies and the Companies’ Subsidiaries, including all
full-time, part-time, temporary and “as needed” employees, including each such
employee’s position, salary and specifying the benefits in which such employee
is enrolled as of the business day prior to the date of this Agreement.  The
first business day following the execution of this Agreement, the Shareholder
shall provide to the Buyer a supplemented Schedule 5.18.1(i), providing the
corresponding names of each employee. There are no individuals who are
independent contractors or consultants with whom the Companies and Companies’
Subsidiaries contract for nursing or therapy services. Schedule 5.18.1(ii) sets
forth a list of all nurse staffing and therapy companies with which the
Companies and the Companies’ Subsidiaries has entered into a written agreement.
Within ten (10) business days following the execution of this Agreement, the
Shareholder shall use diligent efforts to provide to the Buyer a list of those
individuals (by name and position) who have provided services to the Companies
and/or the Companies’ Subsidiaries during the prior three (3) month period
pursuant to contracts with the nursing and/or therapy services companies listed
on Schedule 5.18.1(ii).
 
5.18.2 Each of the Companies and the Companies’ Subsidiaries is in material
compliance with all applicable Laws respecting employment and employment
practices, terms and conditions of employment, wages and hours, occupational
safety and health, including without limitation, ERISA, the Immigration Reform
and Control Act of 1986, the National Labor Relations Act, the Civil Rights Acts
of 1966 and 1964, the Equal Pay Act, the Age Discrimination in Employment Act,
the Americans with Disabilities Act, the Family and Medical Leave Act of 1993,
the Worker Adjustment and Retraining Notification Act, the Occupational Safety
and Health Act, the Davis-Bacon Act, the Walsh-Healy Act, the Service Contract
Act, Executive Order 11246, the Fair Labor Standards Act and the Rehabilitation
Act of 1973 and all regulations under such acts (collectively, the “Labor
Laws”), and none of the Companies nor any of the Companies’ Subsidiaries is
liable for any Liabilities, judgments, decrees, orders, arrearage of wages or
Taxes, fines or penalties for failure to comply with any of the Labor Laws.
 
 
22

--------------------------------------------------------------------------------

 
5.18.3 Except as disclosed on Schedule 5.18.3:
 
(i) There are no charges, governmental audits, investigations, administrative
proceedings or complaints concerning the Companies or any of the Companies’
Subsidiaries employment practices pending or, to the Companies’ knowledge,
threatened before any Governmental Authority or court, and, to the Companies’
knowledge, no basis for any such matter exists;
 
(ii) All current employees, consultants and independent contracts performing
services for or on behalf of the Companies and the Companies’ Subsidiaries
possess and at all times under the employ of the Companies and the Companies’
Subsidiaries have maintained all valid licenses, registrations and
certifications required by any federal or state board or agency charged with
regulating the activities of health care practitioners;
 
(iii) To the Companies’ knowledge, there are no inquiries, investigations or
monitoring of activities of any licensed, registered, or certified personnel
employed by, credentialed or privileged by, or otherwise providing health care
services on behalf of the Companies or any of the Companies’ Subsidiaries
pending or threatened by any federal or state board or agency charged with
regulating the professional activities of health care practitioners;
 
(iv) None of the Companies nor any of the Companies’ Subsidiaries is a party to
any union or collective bargaining agreement or any other agreement regarding
the rates of pay or working conditions of any employees of the Companies or any
of the Companies’ Subsidiaries, and, to the Companies’ knowledge, no union
attempts to organize the employees of the Companies or any of the Companies’
Subsidiaries have been made, and, to the Companies’ knowledge, there are no such
attempts now threatened; and
 
(v) None of the Companies nor any of the Companies’ Subsidiaries has experienced
any organized slowdown, work interruption, strike, or work stoppage by its
employees.
 
5.18.4 None of the Companies nor any of the Companies’ Subsidiaries
has  effectuated (i) a “plant closing” (as defined in the Worker Adjustment and
Retraining Notification Act (the “WARN Act”)) affecting any site of employment
or one or more facilities or operating units within any site of employment or
facility; or (ii) a “mass layoff” (as defined in the WARN Act) affecting any
site of employment or facility; and none of the Companies nor any of the
Companies’ Subsidiaries has been affected by any transaction or engaged in
layoffs or employment terminations sufficient in number to trigger application
of any similar Law.  None of the Companies’ nor any of the Companies’
Subsidiaries’ employees has suffered an “employment loss” (as defined in the
WARN Act) more recently than six (6) months prior to the Closing Date.
 
5.19 Brokerage. Except as set forth on Schedule 5.19 to the Companies’
knowledge, neither the Companies nor the Companies’ Subsidiaries has any
liability or obligation to pay any brokerage commissions, finders’ fees or
similar compensation in connection with the transactions contemplated by this
Agreement based on any arrangement or agreement made by the Companies or the
Companies’ Subsidiaries prior to the Closing Date.
 
 
23

--------------------------------------------------------------------------------

 
5.20 Licenses, Authorizations and Provider Programs.
 
5.20.1 The Companies and the Companies’ Subsidiaries, as applicable are: (i) the
holders of all valid licenses and other rights, permits and authorizations
required by Law or any Governmental Authority to be owned or possessed by the
Companies and the Companies’ Subsidiaries for the conduct of their respective
businesses as presently conducted; (ii) certified for participation and
reimbursement under Titles XVIII and XIX of the Social Security Act to
participate in Medicare and such other similar federal reimbursement or
governmental programs, and those Medicaid programs listed on Schedule 5.20.1 
for which the Companies and/or the Companies’ Subsidiaries are eligible to
receive payments on account of services provided by them (the “Government
Programs”); (iii) the holders of current provider agreements for such Government
Programs; and (iv) the holders of current provider agreements with certain
private non-governmental programs listed on Schedule 5.20.1 (“Private
Programs”).  Set forth on Schedule 5.20.1 is a correct and complete list of such
licenses, permits and other authorizations under all Government Programs and
Private Programs. Except as noted on Schedule 5.20.1, true, complete and correct
copies of all items listed on Schedule 5.20.1 have been provided to
Buyer.  True, complete and correct copies of all surveys of the Companies and/or
the Companies’ Subsidiaries conducted in connection with any Government Program,
Private Program or licensing or accrediting body during the past five (5) years
have been provided to Buyer.
 
5.20.2 No material violation, default, or deficiency by Companies or Companies’
Subsidiaries exists with respect to any of the items listed on Schedule
5.20.1.  None of the Companies nor any of the Companies’ Subsidiaries has
received within the past three (3) years, and to the Companies’ knowledge none
of the Companies nor any of the Companies’ Subsidiaries has received prior to
such three (3) year period,  any written notice of any action pending or
recommended by any Governmental Authority having jurisdiction over the items
listed on Schedule 5.20.1, either to revoke, limit, withdraw or suspend any
license, right or authorization, or to terminate the participation of the
Companies or any of the Companies’ Subsidiaries in any Government Program or
Private Program.  To the Companies’ knowledge, no event has occurred which, with
the giving of notice, the passage of time, or both, would constitute grounds for
a violation, order or deficiency with respect to any of the items listed on
Schedule 5.20.1 or to revoke, limit, withdraw or suspend any such item, or to
terminate or modify the participation of the Companies or any of the Companies’
Subsidiaries in any Government Program or Private Program.  To the Companies’
knowledge, there has been no decision not to renew any provider or third-party
payor agreement between any of the Companies or any of the Companies’
Subsidiaries and a Government Program or Private Program.  No current employee,
agent or contractor of any of the Companies or any of the Companies’
Subsidiaries has been excluded from or prohibited from providing services under
any federal or state health care program, including but not limited to the
Medicare and Medicaid programs.
 
 
24

--------------------------------------------------------------------------------

 
5.20.3 The Companies and each of the Companies’ Subsidiaries have timely filed
all cost reports and other reports required to be filed by them prior to the
date hereof with respect to the Government Programs and Private Programs.  All
such reports are complete and accurate in all material respects and have been
prepared in compliance with all applicable Laws governing reimbursement and
payment of claims.  All cost reports have been accepted (as provided in the CMS
Provider Reimbursement Manual Publication 15-1) by the applicable Regional Home
Health Care Intermediaries or Medicare Administrative Contractors with which
such cost reports were filed.  True and complete data pertaining to the
Companies and the Companies’ Subsidiaries provided on cost reports filed for
2012 have been delivered to Buyer.  To the Companies’ knowledge, the Companies
and the Companies’ Subsidiaries, as applicable, (i) have paid or caused to be
paid or have properly reflected in the Financial Statements all known and
undisputed refunds, overpayments, discounts or adjustments, including but not
limited to any Hospice Medicare cap liability, which have become due pursuant to
such reports and related to the Companies or the Companies’ Subsidiaries and
(ii) have no Liability under any Government Program or Private Program for any
refund, overpayment, discount or adjustment for services provided in the
operation of the Companies or the Companies’ Subsidiaries other than in the
ordinary course or except as has been specifically reserved for in the Financial
Statements or disclosed herein or in the Schedules hereto, including Liabilities
discovered as a result of audits conducted by recovery audit contractors, zone
program integrity contractors, or similar investigative agencies on behalf of
any Government Program and interest or penalties accruing with respect
thereto.  To the Companies’ knowledge, there is no basis for any claim or
request for recoupment or reimbursement by any Governmental Authority or other
provider reimbursement entity relating to the Government Programs in connection
with the Companies or the Companies’ Subsidiaries.  Except as set forth on
Schedule 5.20.3, during the past three (3) years, there have been no claims for
refunds, overpayments, discounts or adjustments with respect to the Companies or
the Companies’ Subsidiaries as a result of audits conducted by recovery audit
contractors, zone program integrity contractors, or similar investigative
agencies on behalf of any Government Program.  To the Companies’ knowledge,
there are no pending appeals, adjustments, challenges, audits, litigation or
notices of intent to reopen any closed cost reports filed with respect to the
Companies or the Companies’ Subsidiaries.  There are no other reports required
to be filed by the Companies or the Companies’ Subsidiaries in order to be paid
under any Government Program or Private Program for services rendered, except
for cost reports not yet due.
 
5.21 Officers and Directors. Schedule 5.21 lists all officers and directors of
the Companies and the Companies’ Subsidiaries as of the date hereof.
 
5.22 Bank Accounts. Schedule 5.22 lists all of the bank accounts of the
Companies and the Companies’ Subsidiaries as of the date hereof.
 
5.23 Healthcare Laws.
 
5.23.1  The Companies and the Companies’ Subsidiaries have been and are
currently operating their respective businesses in material compliance with all
applicable Health Care Laws. To the Companies’ knowledge, no owner, officer, or
director the Companies or the Companies’ Subsidiaries, or any other Person, has
engaged in any act on behalf of the Companies or the Companies’ Subsidiaries,
that violates the Health Care Laws.
 
5.23.2 None of the Companies nor any of the Companies’ Subsidiaries has received
any written communication from a Governmental Authority that alleges that it is
not in compliance with any Health Care Law, other than statements of
deficiencies from a governmental authority received in the ordinary course of
business.
 
 
25

--------------------------------------------------------------------------------

 
5.23.3 None of the Companies nor any of the Companies’ Subsidiaries has been
subpoenaed or charged or, to the Companies’ knowledge, investigated in
connection with any possible violation of any Health Care Law, but excluding
therefrom any surveys or investigations in the ordinary course of business
regarding compliance with Medicare conditions of participation or state
licensure requirements.
 
5.23.4 To the Companies’ knowledge, each of the Companies and the Companies’
Subsidiaries, as applicable, has properly and legally billed for all items and
services furnished and have maintained records supporting the provision of
services billed in accordance with Health Care Laws.  No funds are now, or to
the Companies knowledge will be, withheld from the Companies or the Companies’
Subsidiaries pursuant to any Health Care Law.
 
5.23.5 To the Companies’ knowledge, none of the Companies, nor any of the
Companies’ Subsidiaries, nor any current employee thereof has been excluded or
is threatened with exclusion from participation in any Federal health care
program, as such term is defined in section 1128B(f) the Social Security Act, 42
U.S.C. § 1320a-7b(f).
 
5.23.6 In accordance with 42 CFR §424.550(b), each of the Companies and the
Companies’ Subsidiaries warrants, with respect to its respective provider
number, that it has not experienced a change of majority ownership, as that term
is interpreted under 42 CFR §424.550(b), during the thirty-six (36) months
preceding the Closing Date.  Further, each of the Companies and the Companies’
Subsidiaries warrants that it has the power to transfer the Governmental Program
provider numbers listed in Schedule 5.20.1 to Buyer provided that any required
consent or approval of, prior filing with or notice to, or any action by, any
Governmental Authority is fulfilled, and that no transaction or event has
occurred that would prevent the Companies and the Companies’ Subsidiaries from
transferring those Governmental Program provider numbers set forth on Schedule
5.20.1 to Buyer.
 
5.23.7 In accordance with 42 CFR §424.535, 42 CFR §424.502, and 42 CFR §489.52,
with respect to the Governmental Program provider numbers to be transferred to
Buyer under this Agreement, each of the Companies and the Companies’
Subsidiaries warrants that it has not undergone a cessation of business and has
remained operational as defined in 42 CFR §424.502.  There is no violation,
default, or deficiency that exists with respect to the Governmental Program
provider numbers owned by the Companies or the Companies’ Subsidiaries that
would give cause for termination of the provider agreement or revocation of
enrollment or billing privileges by any Government Program.
 
5.24 Inspections and Investigations.  Except as set forth and described in
Schedule 5.24: (i) each of the Companies’ and the Companies’ Subsidiaries’, as
applicable, right to receive reimbursements pursuant to any Government Program
or Private Program has not been terminated or otherwise adversely affected as a
result of any investigation or action whether by any Governmental Authority or
other third party; (ii) none of the Companies nor the Companies’ Subsidiaries
has during the past three (3) years, been the subject of any non-ordinary course
inspection, investigation, survey, audit, monitoring or other form of review by
any Governmental Authority, professional review organization, accrediting
organization or certifying agency based upon any alleged improper activity on
the part of such entity, and  none of the Companies nor the Companies’
Subsidiaries has received any written notice of material deficiency during the
past three (3) years in connection with its operations; (iii) there are not
presently, and at the Closing Date, there will not be, any outstanding
deficiencies or work orders of any Governmental Authority having jurisdiction
over any of the Companies or the Companies’ Subsidiaries, requiring conformity
to any applicable agreement, Law or bylaw or rule, including but not limited to,
the Government Programs and Private Programs; and (iv) to the Companies’
knowledge, there is not any notice of any claim, requirement or demand of any
Governmental Authority or other third party supervising or having authority over
any of the Companies or the Companies’ Subsidiaries or their operations to
rework or redesign any part thereof or to provide additional furniture,
fixtures, equipment, appliances or inventory so as to conform to or comply with
any existing Law or standard.  The Companies have provided to Buyer true and
complete copies of all reports, correspondence, notices and other documents
relating to any matter described or referenced on Schedule 5.24, other than any
such items that are protected by the attorney-client privilege or other
applicable privilege (a list of such privileged items has been provided to
Buyer).
 
 
26

--------------------------------------------------------------------------------

 
5.25 Suppliers.   Schedule 5.25 sets forth a true, complete and correct list of
the six (6) largest suppliers of the Companies and the Companies’ Subsidiaries
(the “Top Suppliers”) by dollar volume of purchases for each of 2012 and 2013.
Except as set forth on Schedule 5.25, since the Latest Balance Sheets, neither
the Companies nor the Companies’ Subsidiaries has received any written
indication from any Top Supplier to the effect that such Top Supplier will stop
supplying materials, products or services to the Companies or any Companies’
Subsidiaries, which could reasonably be expected to have a Material Adverse
Effect.
 
5.26 No Undisclosed Liabilities.   Except as set forth in Schedule 5.26 or as
would not have a Material Adverse Effect, none of the Companies, nor any of the
Companies’ Subsidiaries has any Liability or obligation of any nature (whether
known or unknown, whether asserted or unasserted, whether absolute or
contingent, whether accrued or unaccrued, whether liquidated or unliquidated,
and whether due or to become due, or otherwise) other than liabilities or
obligations to the extent shown on the Latest Balance Sheets and Current
Liabilities incurred in the ordinary course of business since the date of the
Interim Balance Sheet.
 
5.27 No Other Representations or Warranties. EXCEPT FOR THE REPRESENTATIONS AND
WARRANTIES CONTAINED IN THIS Article 5 (AS QUALIFIED BY THE SCHEDULES HERETO),
THE SHAREHOLDER AND THE COMPANIES MAKE NO EXPRESS OR IMPLIED REPRESENTATION OR
WARRANTY.
 
ARTICLE 6
REPRESENTATIONS AND WARRANTIES OF SHAREHOLDER
 
Shareholder hereby represents and warrants to Buyer that, as of the Closing
Date:
 
6.1 Organization and Authority. Shareholder is a limited liability company duly
organized, validly existing, and in good standing under the Laws of the
jurisdiction of its organization.
 
6.2 Authorization; Valid and Binding Agreement. Shareholder has full power and
authority (including full limited liability company power and authority) to
execute and deliver this Agreement and to perform its obligations hereunder. The
execution and delivery of this Agreement by Shareholder and the consummation by
Shareholder of the transactions contemplated hereby have been duly authorized by
all necessary limited liability company action, and no other company proceedings
on the part of Shareholder and no member vote is necessary to authorize this
Agreement or to consummate the transactions contemplated hereby. This Agreement
constitutes the valid and legally binding obligation of Shareholder, enforceable
in accordance with its terms and conditions, subject to Laws of general
application relating to public policy, bankruptcy, insolvency and the relief of
debtors and rules of Law governing specific performance, injunctive relief and
other equitable remedies.
 
 
27

--------------------------------------------------------------------------------

 
6.3 No Breach. The execution, delivery and performance of this Agreement by the
Shareholder and the consummation of the transactions contemplated hereby will
not (i) result in any breach of, constitute a default under or result in a
violation of the provisions of the Shareholder’s certificate of formation,
operating agreement or other organizational documents, (ii) conflict with,
result in a breach of, constitute a default under, result in the acceleration
of, create in any party the right to accelerate, terminate, modify, or cancel,
or require any notice or consent under any agreement, contract, lease, license,
instrument, or other arrangement to which the Shareholder is a party or by which
it is bound or to which any of the Shares are subject, (iii) result in the
imposition or creation of a Lien upon or with respect to Shares, (iv) violate
any applicable Law, order, judgment or decree to which the Shareholder is
subject, or (v) require the Shareholder to obtain any authorization, consent or
approval of or require the Shareholder to provide any notice to or make any
filing with any Governmental Entity under the provisions of any applicable Law,
order, judgment or decree to which the Shareholder is subject.
 
6.4 Litigation. There are no actions, suits or proceedings currently pending or,
to Shareholder’s knowledge, threatened against Shareholder or any of its
Affiliates, at Law or in equity, before or by any Governmental Entity, which
could interfere with Shareholder’s ability to close this transaction.
 
6.5 Title to Shares, Etc. Shareholder is the record and beneficial owner of, and
has good and marketable title to, the Shares free and clear of all Liens,
agreements, voting trusts, proxies and other arrangements or restrictions of any
kind whatsoever. Neither Shareholder nor any other Person owns any other
securities of the Companies other than the Shares, and, except for this
Agreement, there are no agreements or other rights or arrangements existing
which provide for the sale, purchase, exchange or other transfer by Shareholder
of any of the Shares or any other security of the Companies.
 
6.6 Brokerage. Except as set forth on Schedule 6.6, there are no claims for
brokerage commissions, finders’ fees or similar compensation in connection with
the transactions contemplated by this Agreement based on any arrangement or
agreement made by or on behalf of the Shareholder, the Companies, or the
Companies’ Subsidiaries.
 
6.7 No Other Representations or Warranties. EXCEPT FOR THE REPRESENTATIONS AND
WARRANTIES CONTAINED IN Article 5 AND Article 6 (AS QUALIFIED BY THE SCHEDULES
HERETO), THE SHAREHOLDER MAKES NO EXPRESS OR IMPLIED REPRESENTATION OR WARRANTY.
 
 
28

--------------------------------------------------------------------------------

 
ARTICLE 7
REPRESENTATIONS AND WARRANTIES OF BUYER
 
Buyer hereby jointly and severally represents and warrants to the Shareholder,
the Companies, and the Companies’ Subsidiaries that:
 
7.1 Organization and Authority. Each Buyer is a limited liability company duly
organized, validly existing, and in good standing under the Laws of the
jurisdiction of its formation as reflected on the signature page hereto. Each
Buyer is a wholly owned subsidiary of LHC.
 
7.2 Authorization; Valid and Binding Agreement. Buyer has full power and
authority (including full corporate or other entity power and authority) to
execute and deliver this Agreement and to perform its obligations hereunder. The
execution and delivery of this Agreement by Buyer and the consummation by Buyer
of the transactions contemplated hereby have been duly authorized by all
necessary corporate action, and no other corporate proceedings on the part of
Buyer and no stockholder votes are necessary to authorize this Agreement or to
consummate the transactions contemplated hereby. This Agreement constitutes the
valid and legally binding obligation of Buyer, enforceable in accordance with
its terms and conditions, subject to Laws of general application relating to
public policy, bankruptcy, insolvency and the relief of debtors and rules of Law
governing specific performance, injunctive relief and other equitable remedies.
 
7.3 Brokerage. Except as set forth on Schedule 7.3, there are no claims for
brokerage commissions, finders’ fees or similar compensation in connection with
the transactions contemplated by this Agreement based on any arrangement or
agreement made by or on behalf of Buyer.
 
7.4 Litigation. There are no actions, suits or proceedings currently pending or,
to Buyer’s knowledge, threatened against Buyer or any of its Affiliates, at Law
or in equity, before or by any Governmental Entity, which could interfere with
Buyer’s ability to close this transaction.
 
7.5 Financing. Buyer has (and at Closing shall have) sufficient unrestricted
cash or other sources of immediately available unrestricted funds to enable
Buyer to consummate the transactions contemplated by this Agreement, to satisfy
its obligations hereunder on and after the Closing Date and to make payment of
all amounts to be paid by it under this Agreement on and after the Closing Date.
 
7.6 No Knowledge of Misrepresentations or Omissions. Buyer, including its agents
and advisors, has no knowledge that any of the representations and warranties of
Companies and/or the Shareholder in this Agreement are untrue or incorrect in
any material respect.
 
7.7 No Other Representations or Warranties. EXCEPT FOR THE REPRESENTATIONS AND
WARRANTIES CONTAINED IN THIS Article 7 (AS QUALIFIED BY THE SCHEDULES HERETO),
THE BUYER MAKES NO EXPRESS OR IMPLIED REPRESENTATION OR WARRANTY.
 
 
29

--------------------------------------------------------------------------------

 
ARTICLE 8
BUYER’S CONDITIONS PRECEDENT TO CLOSING
 
The obligations of Buyer to consummate the transactions described in this
Agreement are subject to the satisfaction, before the Effective Time, of the
following conditions precedent, any of which may be waived in writing by Buyer.
 
8.1 Covenants to be Performed. The Shareholder, the Companies and the Companies’
Subsidiaries shall have performed in all material respects all of the covenants
and agreements required to be performed by them under this Agreement at or prior
to the Closing.
 
8.2 No Judgment, Decree or Order. There must not have been any judgment, decree
or order entered after the date hereof by any Governmental Entity which would
prevent the consummation of the Closing on the Closing Date.
 
8.3 Supporting Documents. Buyer shall have received the documents set forth
below:
 
8.3.1 Certificate(s) representing all of the Shares, free and clear of all
Liens, with any necessary federal, state and local transfer stamps affixed
thereto, duly endorsed or accompanied by duly executed stock powers, in the form
attached hereto as Exhibit 8.3.1;
 
8.3.2 Certificate(s) representing all of the ownership interests of the
Companies’ Subsidiaries;
 
8.3.3 A certificate signed by an authorized officer of the Shareholder dated the
Closing Date and certifying that (i) the representations and warranties of the
Companies and the Shareholder set forth in Article 5 and Article 6 hereof are
true and correct at and as of the Closing Date, as though then made (other than
those representations and warranties that address matters as of particular
dates, in which case such representations and warranties shall be true and
correct as of such particular dates), except to the extent that failure of such
representations and warranties to be true and correct as of such date do not
result in a Material Adverse Effect, and (ii) as of the Closing Date, that
condition set forth in Section 8.1 is satisfied.
 
8.3.4 Certificates of the Secretary or an Assistant Secretary of the Companies
and the Companies’ Subsidiaries dated the Closing Date and certifying: (i) that
attached thereto is a true and complete copy of the organizational documents
(e.g., Articles of Incorporation/Organization and Bylaws/Operating Agreement) of
such entity as in effect on the date of such certification; and (ii) that the
organizational documents have not been amended since the date of the last
amendment referred to in the organizational documents attached pursuant to
subsection (i) above;
 
8.3.5 A certificate of the Secretary or an Assistant Secretary of the
Shareholder dated the Closing Date and certifying that attached thereto is a
true and complete copy of all resolutions adopted by the Managers of the
Shareholder authorizing the execution, delivery and performance of this
Agreement and the ancillary agreements and all transactions contemplated by this
Agreement and that all such resolutions are in full force and effect as of the
Closing Date; and
 
 
30

--------------------------------------------------------------------------------

 
8.3.6 Certificates of good standing for the Companies and the Companies’
Subsidiaries from the Secretary of State of the jurisdiction in which such
entity was formed dated no more than five (5) days prior to Closing.
 
8.4 Satisfaction of Indebtedness; Release of Liens. Buyer shall have received
correspondence or documentation reasonably acceptable to the Buyer evidencing
the release and satisfaction of (i) all Indebtedness of the Companies and the
Companies’ Subsidiaries (other than accounts payable) and (ii) all Liens (other
than Permitted Liens) on all of the assets of the Companies and the Companies’
Subsidiaries.
 
8.5 Third Party Consents. All required third party consents/approvals to the
consummation of the transactions contemplated hereby which are listed on
Schedule 8.5 shall have been obtained.
 
8.6 No Material Adverse Effect.  There shall not have occurred any Material
Adverse Effect between the date hereof and the Closing Date and a certificate of
a duly authorized officer of the Shareholder shall have been delivered to Buyer
to such effect.
 
8.7 Necessary Consents and Approvals.  Buyer and the Companies shall have
obtained those new certificates of need, certificates of exemption, regulatory
approvals, licenses, consents and permits to which the Companies and the
Companies Subsidiaries are subject which are listed on Schedule 8.7 (“Necessary
Consents and Approvals”) which are required by Law to be issued prior to or on
Closing in order for the Buyer to be legally entitled to continue to provide
services in the manner provided by the Company and the Company Subsidiaries
prior to the Closing Date.
 
8.8 Transfer of Assets to Operating Newcos. The assets which are currently
solely used in, and the operating liabilities which arose solely from, the
operation of the home health businesses of the Excluded Companies, which
collectively conduct home health operations in the States of Nebraska, Illinois
and Kentucky at the locations set forth on Exhibit A hereto, shall have been
transferred to the Operating Newcos.
 
ARTICLE 9
SHAREHOLDER’S CONDITIONS PRECEDENT TO CLOSING
 
The obligation of Shareholder to consummate the transactions described in this
Agreement is subject to the satisfaction, before the Effective Time, of the
following conditions precedent, any of which may be waived in writing by
Shareholder:
 
9.1 Covenants to be Performed. The Buyer shall have performed in all material
respects all of the covenants and agreements required to be performed by it
under this Agreement at or prior to the Closing.
 
9.2 No Judgment, Decree or Order. There must not have been any judgment, decree
or order entered after the date hereof by any Governmental Entity which would
prevent the consummation of the Closing on the Closing Date.
 
9.3 Supporting Documents. Shareholder shall have received the documents set
forth below:
 
 
31

--------------------------------------------------------------------------------

 
9.3.1 A certificate signed by an authorized officer of each Buyer dated the
Closing Date and certifying that (i) the representations and warranties of the
Buyer set forth in Article 7 hereof are true and correct at and as of the
Closing Date, as though then made (other than those representations and
warranties that address matters as of particular dates, in which case such
representations and warranties shall be true and correct as of such particular
dates), except to the extent that failure of such representations and warranties
to be true and correct as of such date do not result in a Material Adverse
Effect, and (ii) as of the Closing Date, that condition set forth in Section 9.1
is satisfied.
 
9.3.2 A certificate of the Secretary or an Assistant Secretary of each Buyer
dated the Closing Date and certifying that attached thereto is a true and
complete copy of all resolutions adopted by the Board of Directors of the Buyer
authorizing the execution, delivery and performance of this Agreement and the
ancillary agreements and all transactions contemplated by this Agreement and
that all such resolutions are in full force and effect as of the Closing Date;
and
 
9.3.3 Certificates of good standing for each Buyer from the Secretary of State
of the jurisdiction in which such entity was formed dated no more than five (5)
days prior to Closing.
 
9.4 Purchase Price. Buyer shall pay the Purchase Price as required in Article 4.
 
ARTICLE 10
PRE-CLOSING COVENANTS
 
10.1 Conduct of the Business.
 
10.1.1 Affirmative Covenants of the Companies. From the date hereof until the
earlier of the Closing Date or the termination of this Agreement, unless the
prior written consent of Buyer shall have been obtained (which consent shall not
be unreasonably withheld, conditioned or delayed), and except as otherwise
expressly contemplated herein, the Companies shall (and shall cause each of the
Companies’ Subsidiaries to):
 
(i) Operate the Companies and each of the Companies’ Subsidiaries in accordance
with all applicable Laws and only in the usual, regular, and ordinary course of
business, consistent with past general practices and custom;
 
(ii) Use reasonable commercial efforts to preserve intact the rights, assets,
properties, business organization, licenses, permits, Government Programs,
Private Programs, customers and employee, supplier, patient, referral source and
other relationships of the Companies and each of the Companies’ Subsidiaries;
 
(iii) Use reasonable commercial efforts to retain the services of the employees,
agents and consultants of the Companies and each of the Companies’ Subsidiaries
on terms and conditions not less favorable to the Companies and each of the
Companies’ Subsidiaries than those existing prior to the date hereof and to
ensure that there are no material adverse changes to employee relations of the
Companies and each of the Companies’ Subsidiaries;
 
 
32

--------------------------------------------------------------------------------

 
(iv) Keep and maintain the properties and assets of the Companies and each of
the Companies’ Subsidiaries in their present condition, repair and working
order, except for normal depreciation and wear and tear, and maintain the
Companies and each of the Companies’ Subsidiaries rights and licenses;
 
(v) Make available to the Buyer and its affiliates  true and correct copies of
applicable internal management and control reports (including aging of accounts
receivable, and listings of accounts payable) and financial statements directly
related to the Companies and each of the Companies’ Subsidiaries;
 
(vi) As soon as reasonably practicable after they become available, but in no
event more than thirty (30) days following the end of each calendar month,
deliver to Buyer or its designated Affiliate true and complete copies of its
monthly financial statements with respect to the Companies and each of the
Companies’ Subsidiaries for each calendar month ending after the date of this
Agreement and prior to Closing in the format historically utilized by the
Companies and each of the Companies’ Subsidiaries;
 
(vii) Perform in all material respects all obligations under agreements relating
to or affecting the assets, properties or rights of the Companies and each of
the Companies’ Subsidiaries;
 
(viii) Keep in full force and effect present insurance policies or other
comparable insurance coverage insuring the assets and properties used by the
Companies and each of the Companies’ Subsidiaries; and
 
(ix) Notify the Buyer of (i) any event or circumstance which is reasonably
likely to have a Material Adverse Effect or constitute a breach of any of the
Shareholders or the Companies representations, warranties or covenants contained
herein; (ii) any material unexpected change in the normal course of business or
in the operation of the properties and assets of the Companies or any of the
Companies’ Subsidiaries; and (iii) any governmental complaints, investigations,
hearings, or adjudicatory proceedings (or communications indicating that the
same may be contemplated) involving the Companies or any of the Companies’
Subsidiaries. The Companies shall keep the Buyer fully informed of such events
and shall consult with the Buyer and its affiliates in connection with any
proposed outcome.
 
Notwithstanding the foregoing or anything in Section 10.1.2, the Companies and
the Companies’ Subsidiaries may take all actions reasonably required to do any
of the following without violation or breach of any of the terms or provisions
hereof: (a) use all available cash to repay any Indebtedness prior to the
Closing; (b) transfer to the Companies and the Companies’ Subsidiaries those
assets or rights which are solely used in, and the operating liabilities which
arose solely from, the home health business, hospice, and private duty
businesses operated through the Companies, the Companies’ Subsidiaries, and the
Excluded Companies; and/or (c) transfer from the Companies and the Companies’
Subsidiaries those assets or rights which are not solely used in, and the
operating liabilities which arose solely from, the home health business,
hospice, and private duty businesses operated through the Companies, the
Companies’ Subsidiaries, and the Excluded Companies.
 
 
33

--------------------------------------------------------------------------------

 
10.1.2 Negative Covenants of the Companies.  From the date hereof until the
earlier of the Closing Date or the termination of this Agreement, the Companies
shall not (and shall cause the Companies’ Subsidiaries not to) do any of the
following without the prior written consent of the Buyer (which consent shall
not be unreasonably withheld, conditioned or delayed):
 
(i) Issue, sell or redeem any of the Companies’ or any of the Companies’
Subsidiaries’ capital stock;
 
(ii) Issue, sell or redeem any securities convertible into, or options with
respect to, warrants to purchase, or rights to subscribe for, any capital stock
(as applicable) of the Companies or any Companies’ Subsidiaries;
 
(iii) Effect any stock dividend or stock split or pay any dividend with respect
to the Shares (except for dividends in cash and dividends by the Companies’
Subsidiaries to the Companies);
 
(iv) Amend the Companies  or any of the Companies’ Subsidiaries’ certificate of
incorporation, bylaws or charter or other organizational document, except for
amendments required to comply with its obligations under this Agreement;
 
(v) Take any action outside the ordinary course that would (a) adversely affect
the ability of any party to the transaction to obtain any consents required for
the transactions contemplated thereby, or (b) adversely affect the ability of
any party hereto to perform its covenants and agreements under this Agreement;
or (c) adversely affect the ability of any party to consummate the transactions
contemplated by this Agreement;
 
(vi) Impose, or suffer the imposition, on any of the rights, properties or
assets of the Companies or any of the Companies’ Subsidiaries of any Lien or
permit any such Lien to exist other than any statutory liens relating to
obligations not yet due and payable;
 
(vii) Incur any Liability or obligation, except in the ordinary course of
business and consistent with past practices;
 
(viii) Except for sales of products or services in the ordinary course of
business and other than pursuant to this Agreement, sell, contribute or enter
into any contract to sell or contribute, any interest in any of the rights,
properties or assets of the Companies or any of the Companies’ Subsidiaries;
 
(ix) Purchase or acquire any assets or properties related to the Companies or
any of the Companies’ Subsidiaries, whether real or personal, tangible or
intangible, or sell or dispose of any assets or properties of the Companies or
Companies’ Subsidiaries, whether real or personal, tangible or intangible,
except in the ordinary course of business and consistent with past practices;
 
 
34

--------------------------------------------------------------------------------

 
(x) Grant any increase in compensation or benefits to the employees of the
Companies or any of the Companies’ Subsidiaries, except in the ordinary course
and in accordance with past practice; pay any severance or termination pay or
any bonus to any of such employees other than pursuant to written policies or
written contracts in effect as of the date hereof and disclosed to the Buyer; or
enter into or amend any severance or employment agreements with employees of the
Companies or any of the Companies’ Subsidiaries;
 
(xi) Enter into or amend any medical director agreements or agreements with
physicians, or with anyone engaged as a medical director or physician, as the
case may be, by the Companies or any of the Companies’ Subsidiaries;
 
(xii) Except for new hires in the ordinary course of business and current
employees in the ordinary course of business, enter into any written employment
agreement with any employees of the Companies or the Companies’ Subsidiaries;
 
(xiii) Commence any litigation involving any right, property, asset or Liability
of the Companies or any of the Companies’ Subsidiaries other than in the
ordinary course of business consistent with past practice, or settle any
litigation involving any right, property, asset or Liability of the Companies or
any of the Companies’ Subsidiaries for restrictions upon the operations of the
Companies or any of the Companies’ Subsidiaries or material money damages;
 
(xiv) Except as required by Law or a determination of a Governmental Entity that
is final, revoke or otherwise change any material election with respect to Taxes
or Tax Returns of the Companies or any of the Companies’ Subsidiaries;
 
(xv) Except in the ordinary course of business and in a manner that is not
material, modify, amend or terminate any contract related to or benefiting the
Companies or any of the Companies’ Subsidiaries or waive, release, compromise or
assign any rights or claims related to or benefiting the Companies or any of the
Companies’ Subsidiaries; or
 
(xvi) Make or commit to make any capital expenditure, or enter into any lease of
capital equipment as lessee or lessor, related to the Companies or the
Companies’ Subsidiaries outside of budget in an amount in excess of $25,000 for
all such items.
 
10.2 Access to Books and Records. During the period from the date hereof to the
earlier of immediately prior to the Closing and the date that this Agreement is
terminated in accordance with its terms, the Companies shall give, and shall
cause their Affiliates to give, Buyer and its authorized representatives
reasonable access to designated personnel, books and records of the Companies
and the Companies’ Subsidiaries that are in the possession or under the control
of the Companies and their Affiliates to the extent relating to the transition
of the Company and the Companies’ Subsidiaries to Buyer; provided that any such
access (i) shall be during normal business hours on reasonable notice,
(ii) shall not, except as otherwise agreed in writing by the Companies, include
sampling or testing of soil, sediment, surface or ground water and/or building
material, (iii) shall not be required where such access would be prohibited or
otherwise limited by, or would be in violation of, any applicable Law (including
HIPAA) or agreement and (iv) shall not otherwise unreasonably interfere with the
conduct of the business of the Companies and the Companies’ Subsidiaries.
 
 
35

--------------------------------------------------------------------------------

 
10.3 Conditions. During the period from the date hereof to the earlier of
immediately prior to the Closing and the date that this Agreement is terminated
in accordance with its terms, on and subject to the terms and conditions hereof,
the Companies shall use their commercially reasonable efforts to cause the
conditions set forth in Article 8 and Article 9 to be satisfied and to
consummate the transactions contemplated herein, in each case as promptly as
practicable after the date hereof.
 
10.4 Transition Services. On the Closing Date, BioScrip and LHC shall execute a
transition services agreement in substantially the form attached hereto as
Exhibit 10.4 (“Transition Services Agreement”). From the date of this Agreement
until the Closing Date, BioScrip and LHC shall use good faith efforts to
supplement and finalize the schedules to the Transition Services Agreement
describing services, duration and price. In the event that BioScrip determines
that it reasonably needs for the Companies and/or the Companies’ Subsidiaries to
provide services on behalf of BioScrip or its Affiliates following the Closing,
the parties agree in good faith to negotiate an agreement prior to Closing to
provide for any such services, including reasonable compensation based on costs
incurred by the Companies and/or the Companies’ Subsidiaries in connection with
the provision of such services.
 
10.5 No-Shop. Unless and until this Agreement is terminated pursuant to Article
14 or upon the occurrence of the Closing, none of BioScrip, the Shareholder, the
Companies, the Companies’ Subsidiaries, nor any of their respective Affiliates,
officers, directors, partners, members, employees, agents, or representatives
(each, a “Seller Party” and collectively, the “Seller Parties”)  shall: (i)
solicit, initiate or encourage submission of proposals or offers from any Person
relating to (a) any merger, stock purchase, asset purchase, joint venture,
equity investment, or any other business combination relating to the Companies,
any of the Companies’ Subsidiaries or any of their respective assets or (b) any
transaction that would adversely affect the transactions contemplated by this
Agreement; (ii) participate in any discussions or negotiations regarding, or
furnish to any other Person, any information with respect to, or otherwise
respond to, cooperate or encourage, any effort or attempt by any other Person to
enter into any merger, stock purchase, asset purchase, joint venture, equity
investment or any other business combination relating to the Companies, any of
the Companies’ Subsidiaries or any of their respective assets which would
adversely affect the transactions contemplated by this Agreement; (iii) without
the prior written consent of Buyer, participate in any discussions or
negotiations regarding the establishment of any management, medical director or
similar agreement related to the Companies’ or any of the Companies’
Subsidiaries except as otherwise necessary or appropriate to satisfy any
applicable regulatory requests, or (iv) approve or undertake any of the
foregoing transactions.  If the any of the Seller Parties receives an offer or
proposal relating to any merger, stock purchase, asset purchase, joint venture,
equity investment or any other business combination relating to the Companies,
any of the Companies’ Subsidiaries or any of their respective assets, such
Seller Party shall notify Buyer of the receipt of such offer.
 
10.6 Insurance. The Shareholder shall maintain (or cause to be maintained) at
its sole cost and expense continuing insurance coverage for the Companies and
Companies’ Subsidiaries related to occurrences prior to Closing in amounts
consistent with other coverages maintained by the Shareholder prior to the
Closing.
 
 
36

--------------------------------------------------------------------------------

 
10.7 Resignation of Directors and Officers. The Shareholder shall secure the
resignations of each director and officer of the Companies and the Companies’
Subsidiaries to be effective as of the Closing Date.
 
10.8 Formation of Holding Newcos and Operating Newcos. As soon as practicable
following the execution of this Agreement and prior to Closing, the Shareholder
shall form or cause to be formed Holding Newcos and Operating Newcos. In
connection with the formation of Holding Newcos and Operating Newcos, the
Shareholder shall provide Buyer with copies of the formation documents prior to
filing and allow Buyer a sufficient opportunity to review and provide reasonable
comments to such formation documents.
 
ARTICLE 11
COVENANTS OF BUYER
 
11.1 Access to Books and Records. From and after the Closing, Buyer shall, and
shall cause the Companies and the Companies’ Subsidiaries to, provide the
Shareholder and its Affiliates and their respective authorized representatives
with reasonable access, during normal business hours, to the books, records
(including accountants’ work papers), properties, facilities and employees of
the Companies and the Companies’ Subsidiaries with respect to periods prior to
the Closing Date and/or in connection with any matter relating to or arising out
of this Agreement and/or any of the transactions contemplated hereby (whether or
not relating to periods prior to the Closing Date). Unless otherwise consented
to in writing by the Shareholder, Buyer shall not permit the Companies or the
Companies’ Subsidiaries, for a period of ten (10) years following the Closing
Date, to destroy, alter or otherwise dispose of any of its books and records, or
any portions thereof, relating to periods prior to the Closing Date and/or
matters relating to this Agreement and the transactions contemplated hereby
without first giving at least thirty (30) days’ prior written notice to the
Shareholder and offering to surrender to the Shareholder such books and records
or such portions thereof.
 
11.2 Conditions. From the date hereof until the earlier to occur of the Closing
Date and the date that this Agreement is terminated in accordance with its
terms, on and subject to the terms and conditions hereof, Buyer shall use its
commercially reasonable efforts to cause the conditions set forth in Article 8
and Article 9 to be satisfied and to consummate the transactions contemplated
herein, in each case as promptly as practicable after the date hereof.
 
11.3 Contact with Customers, Suppliers, Etc. Prior to the Closing, Buyer shall
not contact and/or communicate with, and shall cause its Affiliates,
representatives, agents and other advisors not to, contact and/or communicate
with any customer, supplier, vendor, payor, patient, referral source or other
material business relations, of the Companies and/or the Companies’
Subsidiaries, except with the prior written consent of the Shareholder. The
Shareholder and Buyer shall cooperate and coordinate with respect to jointly
contacting and communicating with employees, officers, directors, patients,
payors, referral sources, or other material business relations of the Companies
and/or the Companies’ Subsidiaries in connection with the transactions
contemplated hereby or otherwise with respect to matters pertaining to the
Companies, the Companies’ Subsidiaries and/or any of their respective
businesses. Notwithstanding the foregoing, Buyer and its Affiliates may
communicate with key members of senior management of the Companies and the
Companies Subsidiaries (including, but not limited to, the Vice President of
Operations, Regional Managers and similarly situated members of management) in
connection with the transactions contemplated hereby or otherwise with respect
to matters pertaining to the Companies, the Companies’ Subsidiaries and/or any
of their respective businesses, without obtaining the prior written consent of
the Shareholder.
 
 
37

--------------------------------------------------------------------------------

 
11.4 Confidentiality. Except as specifically provided in Section 12.5 hereof,
Buyer acknowledges that it and its representatives and advisors remain bound by
the letter agreement regarding confidentiality dated as of December 6, 2013 (the
“Confidentiality Agreement”), from BioScrip, Inc. to LHC Group, Inc. Without
limiting the foregoing, and except as required by applicable Law or the rules of
any applicable stock exchange, prior to the Closing Date and after any
termination of this Agreement, Buyer shall hold and shall cause its Affiliates,
officers, directors, employees, accountants, counsel, consultants, advisors and
agents to hold, in confidence, all documents and information concerning the
Companies or the Companies’ Subsidiaries or any of their Affiliates furnished to
Buyer or any of its Affiliates, officers, directors, employees, accountants,
counsel, consultants, advisors and/or agents in connection with the transactions
contemplated by this Agreement in the manner specified in the Confidentiality
Agreement.
 
11.5 Employment; Employee Benefits. Subject to the other provisions of this
Section 11.5, immediately following the execution of this Agreement, Buyer and
its Affiliates shall assess the staffing needs for the business of the Companies
and the Companies’ Subsidiaries following the Closing. Any terminations as a
result of such assessment shall be made by the Companies and/or the Companies’
Subsidiaries to be effective as of or after the Closing. Buyer covenants and
agrees to be responsible for all obligations and liabilities with respect to or
arising out of such terminations and any severance payments owed to persons who
are not selected by Buyer to continue employment with the Companies and/or the
Companies’ Subsidiaries following the Closing. Notwithstanding anything herein
to the contrary, notices of terminations as a result of Buyer’s assessment shall
be provided on or after the Closing, except to the extent otherwise agreed by
the Buyer and the Shareholder. Each employee of the Companies or the Companies’
Subsidiaries that continues with the business of the Companies or the Companies’
Subsidiaries following the Closing will be provided with a wage, salary and
benefit program that is similar to the wage, salary and benefit programs in
place with respect to similarly situated employees of Buyer and its Affiliates
immediately prior to the Closing Date (“Comparable Benefits”), to the extent
such Comparable Benefits are available to such employees of the Companies or the
Companies’ Subsidiaries under Buyer’s benefit programs. Comparable Benefits
shall include, but not be limited to, extended illness benefit banks in
existence as of the Closing; paid time off banks in existence as of the Closing;
welfare benefit plans in existence as of the Closing; and retirement benefit
plans in existence as of the Closing. Except where it would violate applicable
laws or require Buyer to increase benefits to other employees, each employee
will be credited with service with the Companies, any Companies’ Subsidiaries,
Infusion Therapy Specialists, Inc., Scott-Wilson, Inc., or Option Health, Ltd.,
as applicable, for purposes of eligibility, vesting and determination of level
of benefit purposes (but as to accrual of benefits, only with respect to paid
time off and 401(k) matters), except to the extent such credit would result in a
duplication of benefits. In addition, and without limiting the generality of the
foregoing: (a) each employee shall be immediately eligible to participate,
without any waiting time, in any and all employee benefit plans sponsored by
Buyer and its Affiliates for the benefit of employees (except with respect to
Buyer’s 401(k) Plan and Employee Stock Purchase Plan which provide for waiting
periods (which do not exceed ninety (90) days) that cannot be waived) (such
plans, collectively, the “New Plans”); and (b) for purposes of each New Plan
providing medical, dental, pharmaceutical or vision benefits to any employee,
Buyer shall cause all pre-existing condition exclusions and actively-at-work
requirements of such New Plan to be waived for such employee and his or her
covered dependents (as the term “dependents” is defined under the New Plans)
(unless such exclusions or requirements are lawful and applied under a
comparable employee benefit plan in which such employee participated immediately
before the Closing Date (the “Old Plans”), and such employee and his or her
covered dependents (as the term “dependents” is defined under the New Plans)
shall be credited under the New Plans for any eligible expenses incurred during
that portion of the plan year of the Old Plan ending on the date such employee’s
participation in the corresponding New Plan begins for purposes of satisfying
all deductible, coinsurance and maximum out-of-pocket requirements applicable to
such employee and his or her covered dependents (as the term “dependents” is
defined under the New Plans) for the applicable plan year as if such amounts had
been paid in accordance with such New Plan. For avoidance of doubt, the parties
agree and acknowledge that Buyer shall not assume the Old Plans or any other
Employee Benefit Plan maintained by or on behalf of the Companies and/or the
Companies’ Subsidiaries as part of the transactions contemplated by this
Agreement, nor any liabilities or obligations under such Old Plans and Employee
Benefit Plans. The Buyer’s retirement plan(s) shall accept rollovers of
retirement plan accounts, including any participant loans, of the employees of
the Companies and the Companies’ Subsidiaries held in any of the Old Plans. The
employees of the Companies and the Companies’ Subsidiaries shall not be deemed
direct or third party beneficiaries of the covenants contained in this Section
11.5.
 
 
38

--------------------------------------------------------------------------------

 
11.6 WARN Act Notice. At and for a period of ninety (90) days after the Closing
Date, Buyer shall not, and shall cause the Companies and the Companies’
Subsidiaries not to, take any action as would trigger any Liability under the
WARN Act or any similar Laws. Buyer shall be solely responsible for providing
any notice or other filing required under the WARN Act or any similar Laws in
respect of the termination in connection with or after the Closing of the
employment of any employee of the Companies and the Companies’ Subsidiaries, and
shall indemnify and hold the Shareholder and its Affiliates harmless from any
Liability arising from any failure of Buyer to comply fully with this Section
11.6.
 
11.7 Notification. Prior to the Closing, upon discovery of any material
inaccuracy of the representations and warranties contained in this Agreement,
Buyer shall promptly notify the Companies and the Shareholder of such
inaccuracies.
 
ARTICLE 12
ADDITIONAL COVENANTS AND AGREEMENTS
 
12.1 Acknowledgment by Buyer.
 
12.1.1 Buyer acknowledges and agrees that it has conducted to its satisfaction,
an independent investigation and verification of the financial condition,
results of operations, assets, liabilities, properties and projected operations
of the Companies and the Companies’ Subsidiaries and, in making its
determination to proceed with the transactions contemplated by this Agreement,
Buyer has relied on the results of its own independent investigation and
verification and the representations and warranties of the Companies and the
Companies’ Subsidiaries expressly and specifically set forth in this Agreement
(as qualified by the Schedules hereto). BUYER ACKNOWLEDGES AND AGREES THAT SUCH
REPRESENTATIONS AND WARRANTIES BY THE COMPANIES AND THE COMPANIES’ SUBSIDIARIES
CONSTITUTE THE SOLE AND EXCLUSIVE REPRESENTATIONS AND WARRANTIES OF THE
COMPANIES AND THE SHAREHOLDER TO BUYER IN CONNECTION WITH THE TRANSACTIONS
CONTEMPLATED HEREBY, AND BUYER UNDERSTANDS, ACKNOWLEDGES AND AGREES THAT ANY
OTHER REPRESENTATIONS AND WARRANTIES OF ANY KIND OR NATURE EXPRESS OR IMPLIED
(INCLUDING, BUT NOT LIMITED TO, ANY RELATING TO THE FUTURE OR HISTORICAL
FINANCIAL CONDITION OR PROJECTIONS, RESULTS OF OPERATIONS, ASSETS OR LIABILITIES
OF THE COMPANIES) ARE SPECIFICALLY DISCLAIMED BY THE COMPANIES AND THE
SHAREHOLDER.
 
 
39

--------------------------------------------------------------------------------

 
12.2 Tax Matters.
 
12.2.1 Responsibility for Filing Tax Returns.
 
(i) Except as otherwise provided herein, Buyer, at its sole cost and expense,
shall cause the Companies and each of the Companies’ Subsidiaries to prepare and
timely file all Tax Returns of the Companies and each of the Companies’
Subsidiaries due after the Closing Date. To the extent that a Tax Return of any
Company or any of the Companies’ Subsidiaries due after the Closing Date relates
to a Pre-Closing Tax Period or a Straddle Period, such Tax Return shall be
prepared by Shareholder or one of its Affiliates consistent with past practices
(“Shareholder Prepared Return”) and any Taxes on such returns attributable to a
Pre-Closing Tax Period or the portion of the Straddle Period ending on the
Closing Date shall be paid by the Shareholder or included as a Current
Liability. At least ninety (90) days prior to the due date of any Shareholder
Prepared Return, Shareholder shall provide a draft of such Tax Return to the
Buyer for the Buyer’s review and comment. The Buyer shall cause the Companies or
applicable Companies’ Subsidiaries to file such Shareholder Prepared Returns
with only those changes as may be agreed to in writing in advance by
Shareholder.  Except for Buyer Closing Date Transactions, Shareholder or
BioScrip shall include the income of each Company and the Companies’
Subsidiaries (including any deferred items triggered into income under
Regulation 1.1502-13, any excess loss account taken into income under Regulation
1.1502-19 and the effects of a Section 338(h)(10) Election) on Shareholder’s or
BioScrip’s consolidated federal income Tax Returns for all periods through the
Closing Date and Shareholder or BioScrip shall pay any Tax attributable to such
income.
 
(ii) Buyer shall not, and shall not allow Companies or any Companies’
Subsidiaries, to amend any Tax Return of the Companies and the Companies’
Subsidiaries for a Pre-Closing Tax Period or Straddle Period or otherwise
initiate (or otherwise participate in) any other Shareholder Approved Tax Matter
without the prior written permission of the Shareholder, which permission shall
not be unreasonably withheld in instances where such action results in a Tax
Loss for which no indemnity is owed by Shareholder.
 
 
40

--------------------------------------------------------------------------------

 
(iii) Buyer, the Companies and the Shareholder, agree with respect to certain
Tax matters as follows:
 
(A) Buyer, the Companies and the Companies’ Subsidiaries shall cooperate to make
and/or implement all elections and decisions with respect to whether to carry
back or carry forward a net operating loss or other Tax attribute or a Tax
credit incurred  or realized in a Pre-Closing Tax Period by the Companies or any
Companies’ Subsidiaries consistent with the elections and decisions  taken by
the Companies, the Companies’ Subsidiaries, the Shareholder, or its Affiliates
prior to Closing and to minimize the amount of Taxes payable by the Shareholder
or its Affiliates for Pre-Closing Tax Periods.
 
(B) Buyer, the Companies and the Companies’ Subsidiaries shall treat any gains,
income, deductions, losses, or other items realized by the Companies or the
Companies’ Subsidiaries resulting from any Buyer Closing Date Transaction as
occurring on the day after the Closing Date and each party hereto shall (and
cause the Companies or the Companies’ Subsidiaries to) utilize the “next day
rule” in Treasury Regulation Section 1.1502-76(b)(1)(ii)(B) (or any similar
provision of state, local, or non-U.S. applicable Law) for purposes of
reporting such items on applicable Tax Returns.
 
(C) Neither Buyer, the Companies nor the Companies’ Subsidiaries shall make an
election under Treasury Regulation Section 1.1502-76(b)(2) (or any similar
provision of state, local or non-U.S. applicable Law) (or allow the Companies or
the Companies’ Subsidiaries) to ratably allocate items incurred by the Companies
or the Companies’ Subsidiaries.
 
(D) To treat any indemnification payments as adjustments to the Purchase Price.
 
(E) To the extent available and at Buyer’s option, BioScrip, the Shareholder and
the Companies, as applicable, shall join with Buyer in making a timely election
under Section 338(h)(10) of the Code (and any corresponding election under
state, local, and foreign Law) with respect to the purchase and sale of the
Shares hereunder and with respect to each Company Subsidiary that is a
corporation (collectively, a “Section 338(h)(10) Election”). Notwithstanding
Section 12.2.1(iii)(B), Shareholder shall pay any Tax attributable to the making
of the Section 338(h)(10) Election and Shareholder shall indemnify Buyer and the
Company against any adverse consequences arising out of any failure to pay any
such Taxes.  If a Section 338(h)(10) Election is made, the Shareholder, the
Companies, and Buyer agree that the Purchase Price and the liabilities of the
Companies and the Companies’ Subsidiaries (plus other relevant items) shall be
allocated among the assets of the Companies and the Companies’ Subsidiaries for
all purposes (including Tax and financial accounting) as shown on the allocation
schedule (the “Allocation Schedule”). A draft of the Allocation Schedule shall
be prepared by Buyer and delivered to Shareholder within thirty (30) days
following the Closing Date for its approval. If Shareholder notifies Buyer in
writing that Shareholder objects to one or more items reflected in the
Allocation Schedule, Shareholder and Buyer shall negotiate in good faith to
resolve such dispute; provided, however, that if Shareholder and Buyer are
unable to resolve any dispute with respect to the Allocation Schedule within
fifteen (15) days following the Closing Date, such dispute shall be resolved by
the Independent Auditor. The fees and expenses of such Independent Auditor shall
be borne equally by Shareholder and Buyer. Buyer, the Companies and Shareholder
shall file all Tax Returns (including amended returns and claims for refund) and
information reports in a manner consistent with the Allocation Schedule. Any
adjustments to the Purchase Price pursuant to Section 4.2 herein shall be
allocated in a manner consistent with the Allocation Schedule.
 
 
41

--------------------------------------------------------------------------------

 
Unless otherwise required by a determination of a Governmental Entity that is
final, neither Buyer nor the Companies shall file a Tax Return (and Buyer and
the Companies shall not allow the Companies’ Subsidiaries to file a Tax Return)
that is inconsistent with any agreement pursuant to this Section 12.2.1(iii),
and neither Buyer nor the Companies shall take any position (and Buyer and the
Companies shall not allow the Companies’ Subsidiaries to take any position)
during the course of any Tax Contest or other audit or proceedings that is
inconsistent with any agreement pursuant to this Section 12.2.1(iii).
 
12.2.2 Straddle Period Tax Returns. To the extent permissible under applicable
Laws, the parties agree to elect to have each Tax year of the Companies and the
Companies’ Subsidiaries end on the Closing Date and, if such election is not
permitted or required in a jurisdiction such that the Companies and/or any
Companies’ Subsidiaries is required to file a Tax Return for a Straddle Period,
the parties agree to use the following conventions for determining the amount of
Taxes attributable to the portion of the Straddle Period ending on the Closing
Date: (A) in the case of property Taxes and other similar Taxes imposed on a
periodic basis, the amount attributable to the portion of the Straddle Period
ending on the Closing Date shall be determined by multiplying the Taxes for the
entire Straddle Period by a fraction, the numerator of which is the number of
calendar days in the portion of the period ending on the Closing Date and the
denominator of which is the number of calendar days in the entire Straddle
Period; and (B) in the case of all other Taxes (including income Taxes, sales
Taxes, employment Taxes, withholding Taxes), the amount attributable to the
portion of the Straddle Period ending on the Closing Date shall be determined as
if the Companies and/or such Companies’ Subsidiaries filed a separate Tax Return
with respect to such Taxes for the portion of the Straddle Period ending as of
the end of the day on the Closing Date using a “closing of the books
methodology.” For purposes of clause (B), any item determined on an annual or
periodic basis (including amortization and depreciation deductions) shall be
allocated to the portion of the Straddle Period ending on the Closing Date based
on the relative number of days in such portion of the Straddle Period as
compared to the number of days in the entire Straddle Period.
 
12.2.3 Cooperation on Tax Matters. BioScrip, the Shareholder and Buyer shall
(and Buyer shall cause the Companies and the Companies’ Subsidiaries) cooperate
to carry out the provisions of this Article 12, including but not limited to,
(i) assisting in the preparation and timely filing of any Tax Return of the
Companies and the Companies’ Subsidiaries; (ii) assisting in any audit or other
proceeding with respect to the Tax Returns or Taxes of the Companies and the
Companies’ Subsidiaries; (iii) making available any information, records or
other documents relating to any Taxes or Tax Returns of the Companies and the
Companies’ Subsidiaries; (iv) providing any information required to allow the
Shareholder, Buyer, the Companies or any Companies’ Subsidiaries to comply with
any information reporting contained in the Code or other applicable Laws; (v)
timely making any elections required for a Section 338(h)(10) Election; and (vi)
providing certificates or forms, and timely execute any Tax Return, that are
necessary or appropriate to establish an exemption for (or reduction in) any
Transfer Tax.
 
 
42

--------------------------------------------------------------------------------

 
12.2.4 Transfer Taxes. Buyer will pay, and will indemnify and hold the
Shareholder harmless against, any documentary, stamp, stock transfer, or similar
Tax imposed on the Companies, the Companies’ Subsidiaries or one or more
Shareholder as a result of the transactions contemplated by this Agreement and
any related penalties or interest (collectively, “Transfer Taxes”).
 
12.2.5 Tax Contests.
 
(i) If any Governmental Entity issues to the Companies or any Companies’
Subsidiaries (1) a notice of its intent to audit or conduct another proceeding
with respect to a Tax Return or Taxes of the Companies or any Companies’
Subsidiaries for any Pre-Closing Tax Period or Straddle Period or (2) a notice
of deficiency for Taxes for any such period, Buyer shall notify the Shareholder
of its receipt of such communication from the Governmental Entity within ten
(10) days of receipt and provide the Shareholder with copies of all
correspondence and other documents received from the Governmental Entity. The
Companies and such Companies’ Subsidiaries, as applicable, shall control any
audit or other proceeding in respect of any Taxes or Tax Returns of the
Companies and such Companies’ Subsidiaries (a “Tax Contest”); provided, however,
(1) the Shareholder, at the Shareholder’ sole cost and expense, shall have the
right to control (including the settlement or resolution thereof and the
selection of counsel) or  participate in any Tax Contest to the extent it
relates to a Pre-Closing Tax Period and participate in any Tax Contest to the
extent it relates to a Straddle Period; and (2) Buyer shall not, and shall not
allow the Companies and any Companies’ Subsidiaries, to settle, resolve or
abandon a Tax Contest (whether or not the Shareholder participates in or
controls such Tax Contest) for a Pre-Closing Tax Period or Straddle Period
without the prior written permission of the Shareholder (which shall not be
unreasonably withheld, delayed or conditioned).
 
(ii) If the Shareholder elects to control a Tax Contest for a Pre-Closing Tax
Period, (1) the Shareholder shall notify Buyer of such intent; (2) Buyer shall
promptly complete and execute, and promptly cause the Companies, the Companies’
Subsidiaries or other Buyer Indemnified Party, as applicable, to complete and
execute, any powers of attorney or other documents and take other reasonable
actions that the Shareholder requests to allow the Shareholder to control such
Tax Contest; (3) prior to the Shareholder taking control, Buyer shall, and shall
cause the Companies or the Companies’ Subsidiaries, as applicable, to control
such Tax Contest diligently and in good faith and after the Shareholder takes
control, the Shareholder shall control such Tax Contest in good faith; and (4)
while it controls a Tax Contest, the Shareholder shall (A) keep the Buyer
reasonably informed regarding the status of such Tax Contest; (B) allow the
Buyer, the Companies or any Companies’ Subsidiaries, at Buyer’s sole cost and
expense, to participate in such Tax Contest; and (C) not settle, resolve, or
abandon any such Tax Contest if such settlement, resolution, or abandonment
would result in any Buyer Indemnified Party incurring any material Tax that the
Shareholder are not obligated to pay or indemnify under this Agreement without
the prior written consent of the Buyer (which shall not be unreasonably
withheld, delayed, or conditioned).
 
 
43

--------------------------------------------------------------------------------

 
(iii) If the Shareholder elects to participate in a Tax Contest, (1) the
Shareholder shall notify Buyer of such intent; (2) Buyer shall control, or cause
the Companies or the Companies’ Subsidiaries, as applicable, to control, such
Tax Contest diligently and in good faith; and (3) Buyer shall (and shall cause
the Companies and the Companies’ Subsidiaries to) promptly take all actions
necessary to allow the Shareholder (and its counsel) to fully participate in
such Tax Contest; and (4) if requested by the Shareholder, Buyer shall settle
(or cause the Companies or the applicable Companies’ Subsidiaries, as
applicable, to settle) the Tax Contest on terms acceptable to the Governmental
Entity and the Shareholder (provided that such settlement will not result in a
Buyer Indemnified Party incurring any material Tax that the Shareholder are not
required to pay under this Agreement).
 
(iv) If the Shareholder does not control or participate in a Tax Contest
(whether by election or otherwise) that relates to a Pre-Closing Tax Period or
Straddle Period, (1) Buyer shall control, or cause the Companies or the
applicable Companies’ Subsidiaries, as applicable, to control such Tax Contest
diligently and in good faith; and (2) Buyer shall keep the Shareholder
reasonably informed regarding the status of such Tax Contest; and (3) if
requested by the Shareholder, Buyer shall settle (or cause the Companies and/or
the applicable Companies’ Subsidiaries, as applicable, to settle) the Tax
Contest on terms acceptable to the applicable Governmental Entity and the
Shareholder (provided that such settlement will not result in any Buyer
Indemnified Party incurring any Taxes that the Shareholder is not required to
pay under this Agreement).
 
12.2.6 Tax Refunds. All refunds of Taxes (other than refunds of Transfer Taxes
or refunds generated by the carryback of losses or credits attributable to
periods after the Closing Date) of the Companies or any Companies’ Subsidiaries
for any Pre-Closing Tax Period (or portion of a Straddle Period ending on the
Closing Date as determined in accordance with the same principles provided for
in Section 12.2.2) (whether in the form of cash received or a credit or offset
against Taxes otherwise payable) shall be the property of the Shareholder to the
extent such refund was not included as an asset in the computation of the Final
Closing Date Net Working Capital. To the extent that Buyer, the Companies or any
Companies’ Subsidiaries receives a refund that is the property of the
Shareholder, Buyer shall pay the amount of such refund (and interest received
from the Governmental Entity) to the Shareholder for distribution to the
Shareholder in accordance with the terms of this Agreement. The amount due to
the Shareholder shall be payable to the Shareholder ten (10) days after receipt
of the refund from the applicable Governmental Entity (or, if the refund is in
the form of credit or offset, ten (10) days after the due date of the Tax Return
claiming such credit or offset). Buyer shall use commercially reasonable efforts
to claim (and shall cause the Companies and each Companies’ Subsidiaries to use
commercially reasonable efforts to claim) any refunds that will give rise to a
payment to, or on behalf of, the Shareholder under Section 12.2.6.  If any such
refund or credit is subsequently reversed by such Governmental Entity,
Shareholder shall repay such amount within ten (10) days of notice from Buyer.
 
 
44

--------------------------------------------------------------------------------

 
12.2.7 Termination of Tax Sharing Agreements.  Any tax sharing agreement between
the Companies, the Company Subsidiaries and any other member of BioScrip Inc.’s
consolidated group is terminated as of the Closing Date and shall have no
further effect for any taxable year (whether the current year, future year or a
past year).  Shareholder agrees to indemnify Buyer from and against any
liability under such tax-sharing agreements.
 
12.2.8 Indemnity for Consolidated Tax Liability. Shareholder agrees to indemnify
Buyer from and against any liability the Companies or the Company Subsidiaries
may have resulting from, arising out of, relating to, in the nature of, or
caused by any liability of the Companies or any Company Subsidiary for Taxes of
any person under Regulation 1.1502-6 (or any similar provision under state,
local or foreign law).
 
12.3 Further Assurances. From time to time, as and when requested by any party
hereto and at such requesting party’s expense, any other party hereto shall
execute and deliver, or cause to be executed and delivered, all such documents
and instruments and shall take, or cause to be taken, all such further or other
actions as the requesting party may reasonably deem necessary or desirable to
evidence and effectuate the transactions contemplated by this Agreement on and
subject to the terms and conditions hereof. Without limiting the generality of
the foregoing, LHC and Buyer shall take such actions (and following Closing
shall cause the Companies and Companies’ Subsidiaries to take such actions), and
BioScrip and the Shareholder shall assist LHC and Buyer with taking such
actions, as are necessary in order to obtain full releases of all guarantees by
BioScrip or its Affiliates with respect to the liabilities, operations, or
business of the Companies and Companies’ Subsidiaries following the Closing.
 
12.4 Restrictive Covenants

 
12.4.1 Non-Disclosure of Trade Secrets and Confidential Information.
 
(i) None of BioScrip, the Shareholder, its Affiliates, or any of their
respective officers, directors, partners, members, or employees (each, a
“Shareholder Party” and collectively, the “Shareholder Parties”) shall, at any
time after the Effective Date, directly or indirectly transmit or disclose any
Trade Secret to any Person and shall not make use of any such Trade Secret,
directly or indirectly, for its, his or her own benefit, without the prior
written consent of Buyer.
 
(ii) No Shareholder Party shall, at any time after the Effective Date, directly
or indirectly transmit or disclose any Confidential Information to any Person or
make use of any such Confidential Information, directly or indirectly, for its,
his or her own benefit without the prior written consent of Buyer.
 
 
45

--------------------------------------------------------------------------------

 
(iii) Notwithstanding Sections 12.4.1(i) and 12.4.1(ii) above, any Person may
disclose or use any Trade Secret or Confidential Information to the extent, and
only to the extent, that such Trade Secret or Confidential Information (a) is,
or becomes part of, the public domain other than as a result of any violation by
a Shareholder Party under this Agreement; (b) is required to be disclosed by
law, provided that, to the extent practicable, the disclosing or using party
must give Buyer reasonable advance written notice of the proceeding resulting in
such order, so that Buyer may seek a protective order if Buyer chooses to do so;
or (c) is provided to the Shareholder Party by a third party who, to the
Shareholder Party’s knowledge, has not done so in breach of a confidentiality
obligation of that third party.
 
(iv) Shareholder shall, and shall cause each other Shareholder Party to, convey
to Buyer all Trade Secrets and Confidential Information and shall not retain (or
cause any Shareholder Party to retain) any copies of any such materials after
the Effective Date, provided, however, that no Shareholder Party shall be
required to destroy electronic copies of any Trade Secrets or Confidential
Information that is created and/or maintained pursuant to such Shareholder
Party’s standard electronic backup and archival procedures.
 
(v) The restrictions of this Section 12.4.1 shall apply regardless of whether
the Trade Secret or Confidential Information is in written, graphic, computer,
recorded, photographic or any machine-readable form, is orally conveyed to the
Shareholder Party.
 
(vi) Notwithstanding anything herein to the contrary, the Shareholder Parties
may retain a copy of all Confidential Information related to the transactions
contemplated under this Agreement (including, but not limited to, all
documentation provided to Buyer through the Intralinks dataroom) and all Trade
Secrets shared with Buyer in connection with the transactions contemplated under
this Agreement solely for purposes of defending or asserting any claim related
to this Agreement.
 
12.4.2 Non-Competition.  Shareholder acknowledges that the Confidential
Information in the possession of any Shareholder Party would enable such
Shareholder Party to establish goodwill with the patients, customers and
potential customers, suppliers, and sources or potential sources of referrals
who provide products and services on behalf of the Companies and each of the
Companies’ Subsidiaries or who receive services from the Companies or the
Companies’ Subsidiaries and that the Confidential Information constitutes a
valuable asset of the Companies and the Companies’ Subsidiaries.  Shareholder
further acknowledges that it has developed relationships with certain of the
Companies’ and the Companies’ Subsidiaries’ patients and potential patients,
suppliers, contractors or potential contractors, consultants or potential
consultants, and sources or potential sources of referrals.  Accordingly,
BioScrip and Shareholder will (and shall cause each Shareholder Party to) comply
with the provisions of this Section 12.4.2 for the period beginning on the
Effective Date and ending on the third (3rd) anniversary thereof.  During such
three-year period, BioScrip and Shareholder agree that no Shareholder Party
shall directly or indirectly engage in, render services to or become interested
in any manner, as manager, employee, officer, consultant, or partner, or through
ownership (other than holding less than two percent (2%) of the outstanding
equity securities of a Person having securities that are listed for trading on a
national securities exchange), or otherwise, either alone or in association with
others, in any Person that solely provides services that are similar to or
competitive with the services provided by the Companies or the Companies’
Subsidiaries, which restrictions shall be applicable within: (i) the Mississippi
counties set forth on Exhibit 12.4.2; (ii) the Tennessee counties set forth on
Exhibit 12.4.2; (iii) the Kentucky counties set forth on Exhibit 12.4.2; (iv)
the Nebraska counties set forth on Exhibit 12.4.2; and (v) the Illinois counties
set forth on Exhibit 12.4.2 (collectively, the “Restricted Territory”). For the
avoidance of doubt and notwithstanding anything herein to the contrary, nothing
herein shall prohibit a Shareholder Party from (i) acquiring and thereafter
operating a business (including, but not limited to, a predominantly home
infusion business) which includes as a component a home health, hospice, and/or
private duty business which operates within the Restricted Territory, provided
that such home health, hospice, and/or private duty business either (a) accounts
for less than 10% of the revenue of the acquired business, or (b) is divested as
soon as commercially practicable, but in no event later than  twelve (12) months
following the acquisition; (ii) providing non-Medicare certified nursing
services within the Restricted Territory in connection with the Shareholder
Parties’ businesses that are not being sold under this Agreement (including, but
not limited to, the Shareholder Parties’ home infusion, medical supplies, and
transitional care businesses), or (iii) jointly marketing the Shareholder
Parties’ businesses that are not being sold under this Agreement (including, but
not limited to, the Shareholder Parties’ home infusion, medical supplies, and
transitional care businesses) or otherwise collaborating or joint venturing with
an unrelated provider or supplier that operates, or has an Affiliate which
operates, a home health, hospice, and/or private duty business (including, but
not limited to, health systems); provided that in conjunction with any such
collaboration or joint venture the Shareholder Parties’ may not provide home
health, hospice, and/or private duty services within the Restricted Territory
during the Restricted Period, but the collaboration or joint venture may provide
such services.
 
 
46

--------------------------------------------------------------------------------

 
12.4.3 Non-Solicitation, Non-Interference and No-Hire.
 
(i) Shareholder acknowledges and agrees that valuable relationships have been
established between the Companies and the Companies’ Subsidiaries and certain
Persons, including, without limitation, customers, patients, and
physicians.  Shareholder further acknowledges and agrees that the aforementioned
relationships constitute a valuable asset of the Companies and the Companies’
Subsidiaries and constitute a significant portion of the goodwill of such
entities that is being purchased by Buyer pursuant to this
Agreement.  Accordingly, Shareholder agrees that for a period of three (3) years
after the Effective Date, no Shareholder Party shall, without the prior written
consent of Buyer, directly or indirectly, solicit, divert, take away or attempt
to solicit, divert or take away any customer, patient, physician or other Person
having business or patient relations with the Companies or the Companies’
Subsidiaries for the purpose of providing services that are similar to or
competitive with the services provided by the Companies or the Companies’
Subsidiaries.  Shareholder further agrees that, for a period of three (3) years
after the Effective Date, no Shareholder Party shall, induce or attempt to
induce any customer, patient, physician, supplier or other Person having
business or patient relations with the Companies or the Companies’ Subsidiaries
to breach an existing contract with the Companies or the Companies’ Subsidiaries
or take any other action intended to damage the relationship between any
customer, patient, physician, supplier or other Person having business relations
with the Companies or the Companies’ Subsidiaries. For the avoidance of doubt,
nothing herein shall prohibit a Shareholder Party from calling upon or providing
services (including, but not limited to, nursing services) to any customer,
patient, physician or other Person, which  had business or patient relations
with the Shareholder Parties’ businesses that are not being sold under this
Agreement (including, but not limited to, the Shareholder Parties’ home infusion
businesses).
 
 
47

--------------------------------------------------------------------------------

 
(ii) Shareholder acknowledges and agrees that the Companies and the Companies’
Subsidiaries have provided healthcare services through a network of persons that
includes both persons actually employed by the Companies and the Companies’
Subsidiaries (“Employees”) as well as other non-employee healthcare providers,
including but not limited to physicians, physician groups, nurses, hospitals,
contractors and consultants (the “Providers”), that have contracted with the
Companies and the Companies’ Subsidiaries to provide healthcare
services.  Shareholder further acknowledges and agrees that the arrangements,
agreements and relationships with the Providers and the services provided by
such Providers are integral to the operations of the Companies and the
Companies’ Subsidiaries and that the loss of such arrangements, agreements and
relations would result in irreparable damages to Buyer.  Accordingly,
Shareholder agrees that, for a period of three (3) years after the Effective
Date, no Shareholder Party shall, without the prior written consent of Buyer,
hire, engage or solicit any Employee who is employed by the Companies and the
Companies’ Subsidiaries as of the Effective Date for a period of 12 months
following their termination of employment with the Companies or the Companies’
Subsidiaries; provided, however, that the foregoing shall not prohibit any
Shareholder Party from (a) posting a general public advertisement for employment
not specifically directed at such Employees and hiring any such Employee who
responds to such general public advertisement; or (b) soliciting and/or hiring
any Employee following Buyer’s determination to terminate such
Employee.  Shareholder further agrees that, for a period of three (3) years
after the Effective Date, no Shareholder Party shall, without the prior written
consent of Buyer, hire, engage or solicit any Provider who is engaged  by the
Companies and the Companies’ Subsidiaries as of the Effective Date, for the
purpose of assisting or creating a relationship with any business entity that is
similar to or competitive with the Companies or the Companies’ Subsidiaries
within the Restricted Territory for a period of 12 months following their
termination of engagement with the Companies or the Companies’ Subsidiaries;
provided, however, that the foregoing shall not prohibit any Shareholder Party
from (a) hiring, engaging or soliciting any Provider that may provide health
care services on behalf of Buyer to patients of Buyer, in connection with the
Shareholder Parties’ businesses within the Restricted Territory that are not
being sold under this Agreement (including, but not limited to, the Shareholder
Parties’ home infusion businesses); or (b) soliciting and/or hiring any Provider
following Buyer’s determination to terminate such Provider.
 
12.5 Public Announcements. Except with respect to issuances required by
applicable Law or the rules of any applicable stock exchange, the parties hereto
shall not issue any non-required report, statement or press release or otherwise
make any other public statement with respect to this Agreement and the
transactions contemplated hereby without prior consultation with and approval
(which shall not be unreasonably withheld) of the other parties. The parties
acknowledge and agree that each party intends to make a public announcement upon
the execution and the closing of this Agreement. Each party agrees to provide
the other party with a prior draft of such public announcement, which shall be
subject to approval of the other parties to the extent required under, and in
accordance with, the terms of this Section 12.5.
 
 
48

--------------------------------------------------------------------------------

 
12.6 Access to Books and Records. From and after the Closing, Shareholder shall,
and shall cause its Affiliates to, provide Buyer, the Companies and the
Companies’ Subsidiaries and their respective authorized representatives with
reasonable access, during normal business hours, to all Shareholder and
Shareholder’s Affiliates’ books and records to the extent pertaining to the
Companies and the Companies’ Subsidiaries, including, but not limited to those
records, reporting systems and platforms identified on Schedule 12.6, with
respect to periods prior to the Closing Date to the extent such access does not
violate any Laws and to the extent reasonably necessary for Buyer, the Companies
and/or the Companies’ Subsidiaries to have access to such information . Unless
otherwise consented to in writing by Buyer, Shareholder shall not, and shall
cause its Affiliates not to, for a period of ten (10) years following the
Closing Date, destroy, alter or otherwise dispose of any of its books and
records, including, but not limited to those records, reporting systems and
platforms identified on Schedule 12.6, pertaining to the Companies and/or the
Companies’ Subsidiaries, or any portions thereof, relating to periods prior to
the Closing Date without first giving at least thirty (30) days’ prior written
notice to Buyer and offering to surrender to Buyer, at Buyer’s sole cost and
expense, such books and records or such portions thereof.
 
ARTICLE 13
INDEMNIFICATION
 
13.1 Survival Period. The representations, warranties, covenants and agreements
of the Companies, the Shareholder and Buyer set forth in this Agreement shall
survive the Closing for a period beginning on the Closing Date and ending on the
date that is eighteen (18) months following the Closing Date and shall
thereafter be of no further force or effect; provided, however, that: (i) the
representations and warranties provided for in Sections 5.1, 6.1 and 7.1
(Organization and Corporate Power), Sections 5.2, 6.2 and 7.2 (Authorization),
and Section 5.4 (Capitalization) (collectively, the “Fundamental
Representations”) shall survive the Closing indefinitely; (ii) the
representations and warranties provided for in Section 5.9 (Tax Matters),
Section 5.20 (Licenses, Authorizations and Provider Programs), 5.23 (Healthcare
Laws.), 5.24 (Inspections and Investigations) shall survive the Closing until
thirty (30) days following the expiration of the applicable statute of
limitations to which claims relating to such representations and warranties may
apply;  (iii) the covenants and agreements of the parties in this Agreement that
specify a different time period (e.g., x years, x days, x months) shall survive
in accordance with their respective terms; and (iv) the covenants in Section
12.2 shall survive the Closing until thirty (30) days following the expiration
of the applicable statute of limitations (including extensions)(any such period
with respect to the survival of representations, warranties, covenants and
agreements shall be referred to herein as a “Survival Period”).
 
13.2 Indemnification by the Shareholder for the Benefit of Buyer.
 
13.2.1 Subject to the applicable provisions and limitations of this Article 13,
after the Closing, the Shareholder shall indemnify Buyer and the Companies, and
each of their respective Affiliates, officers, directors, partners, members,
employees, agents, representatives, successors and permitted assigns (the “Buyer
Indemnified Parties”) from and against any Loss, which each Buyer Indemnified
Party actually suffers as a result of:
 
 
49

--------------------------------------------------------------------------------

 
(i) any breach of any representation and warranty contained in Article 5 or in
Article 6 of this Agreement;
 
(ii) any breach of any covenant or agreement of the Shareholder contained in
this Agreement;
 
(iii) any breach prior to the Closing of any covenant or agreement of the
Companies or the Companies’ Subsidiaries contained in this Agreement to be
performed or complied with prior to the Closing (excluding, for the avoidance of
doubt, any breaches by the Companies or the Companies’ Subsidiaries of covenants
or agreements herein from and after the Closing);
 
(iv) for a period beginning on the Closing Date and ending thirty (30) days
following the expiration of the applicable statute of limitations, Losses
arising from (a) the result of any post-payment review of claims, actions,
audits, investigations, or proceedings conducted by or on behalf of any
Government Programs, including, but not limited to, Medicare administrative
contractors or intermediaries, recovery audit contractors, zone program
integrity contractors, specialty medical review contractors,  or similar
investigative agencies, but only to the extent such Losses arise from dates of
service prior to the Effective Time (“Recoupment Indemnity Matter”); provided,
however, that Recoupment Indemnity Matter shall exclude Losses to the extent
arising from new or different billing policies, procedures and/or practices
implemented by the Buyer with respect to bills submitted by the Companies and/or
the Companies’ Subsidiaries following Closing; and (b) any audits,
investigations, claims, actions, proceedings or lawsuits by the U.S. Department
of Health and Human Services Office of Inspector General, U.S. Department of
Justice, a State Attorney General, State Medicaid agency or other agencies or
persons with respect to healthcare fraud, False Claims Act matters, qui tam or
whistle blower actions, or other intent-based, reckless disregard-based, or
other scienter-based Laws related to the provision of healthcare services or the
submission of healthcare claims by the Companies or the Companies’ Subsidiaries
relating to dates of service prior to the Effective Time (“Special Indemnity
Matter”); and
 
(v)           Tax Losses.
 
13.2.2 Notwithstanding any other provision in this Agreement to the contrary
other than Section 12.2.8 (but subject to the other applicable limitations on
indemnification recovery set forth in this Article 13):
 
(i) the Shareholder shall have no liability under Section 13.2.1(i), unless the
aggregate of all Losses relating thereto for which the Shareholder would be
liable, but for this Section 13.2.2, exceeds on a cumulative basis one percent
(1%) of the Purchase Price (the “Deductible”), and then only to the extent such
Losses exceed the Deductible; provided, however, that the Deductible shall not
apply to any Loss incurred by the Buyer Indemnified Parties as a result of a
breach of the Fundamental Representations;
 
 
50

--------------------------------------------------------------------------------

 
(ii) except to the extent provided in Sections 13.2.2(iii), the Shareholder’s
aggregate liability under Section 13.2 (other than with respect to the
Fundamental Representations made by the Shareholder and the obligations in
Section 12.2.8) shall not exceed an amount equal to ten percent (10%) of the
Purchase Price received by Shareholder (the “General Cap”); and
 
(iii) to the extent that Losses arising under Section 13.2.1(iv)  exceed the
amount of the General Cap, the Shareholder shall be liable for Losses arising
under Sections 13.2.1(iv) as set forth on Schedule 13.2.2(iii).
 
All Losses (including but not limited to, Losses as a result of a breach by
Shareholder of the Fundamental Representations and as a result of Tax Losses),
but not including Losses under  Section 13.2.1(iv)(b) and Section 12.2.8, shall
be counted for purposes of determining whether the General Cap and any
additional caps, as applicable, have been reached.
 
13.2.3 Notwithstanding any other provision in this Agreement to the contrary,
the Shareholder shall not be liable to, or have any obligation to indemnify, any
Buyer Indemnified Party for any Losses (i) resulting from any breach of any
covenant, agreement, representation or warranty to which Buyer had knowledge on
or prior to the Closing Date, (ii) to the extent that such Losses result from or
arise out of a breach of this Agreement by Buyer or actions taken by Buyer, the
Companies, the Companies’ Subsidiaries or any of their respective Affiliates
from and after the Closing Date, (iii) to the extent that such Losses result
from or are increased by the passing of or any change in, after the Effective
Date, any Law of any Governmental Entity in effect on the Effective Date or by
any change in, after the Effective Date, any interpretation or enforcement of
any Law by any Governmental Entity, or (iv) to the extent that an accrual for or
reserve against any such Losses was or is included in the Financial Statements
and/or the Closing Date Net Working Capital (as finally determined pursuant to
Section 4.2). The parties acknowledge and agree that the indemnification
provided by this Article 13 constitutes the sole and exclusive remedies of the
parties to this Agreement for any and all Losses or other claims relating to or
arising from this Agreement or in connection with the transactions contemplated
hereby or any exhibit, schedule or certificate delivered hereunder or otherwise
with respect to the transactions contemplated hereby including, without
limitation, with respect to any misrepresentation or inaccuracy in, or breach
of, any representations or warranties or any breach or failure in performance of
any covenants or agreements made by any party to this Agreement or in any
exhibits or schedules hereto or any certificate delivered hereunder or otherwise
with respect to the transactions contemplated hereby; provided that this
sentence shall not limit any rights Buyer or Shareholder may have (a) under
Section 15.1 with respect to seeking specific performance, injunctive or other
equitable relief, (b) under Article 14 in connection with any termination of
this Agreement prior to the Closing, or (c) under Section 13.9.
 
13.3 Mitigation; Related Matters.
 
13.3.1 The Buyer Indemnified Parties shall use, and shall cause the Companies
and the Companies’ Subsidiaries to use, all commercially reasonable efforts to
mitigate all losses, costs, damages and expenses upon and after becoming aware
of any event which could reasonably be expected to give rise to losses, costs,
damages and expenses that are or may be indemnifiable under this Article 13.
 
 
51

--------------------------------------------------------------------------------

 
13.3.2 The Buyer Indemnified Parties shall not be entitled to recover any Losses
relating to any matter (i) arising under one provision of this Agreement to the
extent that the Buyer Indemnified Parties had already recovered Losses with
respect to such matter pursuant to any other provision of this Agreement or (ii)
to the extent such matter has been included in the calculation of (or otherwise
taken into account in determining) the Purchase Price (including, without
limitation, by virtue of being included in the calculation of the Closing Date
Net Working Capital).
 
13.4 Indemnification by Buyer for the Benefit of the Shareholder.
 
13.4.1 Subject to the applicable provisions of this Article 13, after the
Closing, Buyer shall jointly and severally indemnify the Shareholder and each of
its Affiliates, officers, directors, partners, members, employees, agents,
representatives, successors and permitted assigns (collectively, the
“Shareholder Indemnified Parties”) against any Losses which any of the
Shareholder Indemnified Parties actually suffer as a result of:
 
(i) any breach of any representation or warranty of Buyer contained in this
Agreement,
 
(ii) any breach of any covenant or agreement set forth in this Agreement to be
performed by Buyer and/or, from and after the Closing, the Companies or the
Companies’ Subsidiaries, or
 
(iii) the ownership and/or the operation of the Companies, the Companies’
Subsidiaries and their respective businesses from and after the Closing.
 
13.4.2 Notwithstanding any other provision in this Agreement to the contrary
(but subject to the other applicable limitations on indemnification recovery set
forth in this Article 13):
 
(i) the Buyer shall have no liability under Section 13.4.1(i), unless the
aggregate of all Losses relating thereto for which the Shareholder would be
liable, but for this Section 13.4.2, exceeds on a cumulative basis the
Deductible, and then only to the extent such Losses exceed the Deductible; and
 
(ii) the Buyer’s aggregate liability under Section 13.2 (other than with respect
to the Fundamental Representations made by the Shareholder and other than with
respect to Losses arising under Section 13.4.1(iii)) shall not exceed the
General Cap.
 
All Losses (including but not limited to, Losses as a result of a breach by
Buyer of the Fundamental Representations) shall be counted for purposes of
determining whether the General Cap has been reached.
 
 
52

--------------------------------------------------------------------------------

 
13.5 Manner of Payment. Any indemnification payment pursuant to this Article 13
shall be effected by wire transfer of immediately available funds from (or on
behalf of) the applicable indemnifying party to an account designated by each
applicable indemnified party within twenty-one (21) days after the determination
thereof.
 
13.6 Defense of Third Party Claims. Promptly after the assertion by any third
party of any claim (a “Third Party Claim”) against any Person entitled to seek
indemnification under Section 13.2 or Section 13.4 (an “Indemnitee”) that
results or may result in the incurrence by such Indemnitee of any Loss for which
such Indemnitee desires to seek indemnification under this Article 13, such
Indemnitee shall notify each of the parties from whom such indemnification could
be sought hereunder with respect to such claim (collectively, the “Indemnitor”)
of such claim in writing promptly after receiving notice of such claim,
describing the claim, the amount thereof (if known and quantifiable) and the
basis thereof in reasonable detail (such written notice, an “Indemnification
Notice”); provided that the failure to so notify an Indemnitor shall not relieve
the Indemnitor of its obligations hereunder except to the extent that the
Indemnitor is materially prejudiced thereby. Any Indemnitor shall be entitled to
participate in the defense of such action, lawsuit, proceeding, investigation or
other claim giving rise to an Indemnitee’s claim for indemnification at such
Indemnitor’s expense, and at its option shall be entitled to assume the defense
thereof by appointing a reputable counsel reasonably acceptable to the
Indemnitee to be the lead counsel in connection with such defense; provided that
the Indemnitee shall be entitled to participate in the defense of such claim and
to employ counsel of its choice for such purpose; provided, however, that the
fees and expenses of such counsel shall be borne by the Indemnitee and shall not
be recoverable from such Indemnitor(s) under this Article 13. If the Indemnitor
shall control the defense of any such claim, the Indemnitor shall be entitled to
settle such claims; provided that the Indemnitor shall obtain the prior written
consent of the Indemnitee (which consent shall not be unreasonably withheld,
conditioned and/or delayed) before entering into any settlement of a claim or
ceasing to defend such claim; provided, however, that no such consent will be
required if, pursuant to or as a result of such settlement, there is no
injunctive or other equitable relief that will be imposed against the
Indemnitee, such settlement expressly and unconditionally releases the
Indemnitee from all liabilities and obligations with respect to such claim, and
such settlement does not contain any admission or statement suggesting any
wrongdoing or liability on behalf of the Indemnified Parties. In all cases, the
Indemnitee shall provide, and the Indemnitee shall cause its Affiliates to
provide, their reasonable cooperation with the Indemnitor in defense of claims
or litigation, including by making employees, information and documentation
reasonably available. In no event shall an Indemnitee consent to the entry of
any judgment or enter into any settlement with respect to any Third Party Claim
without the written consent of the Indemnitor (which consent shall not be
unreasonably withheld, conditioned and/or delayed) if any Indemnitee is seeking
or shall seek indemnification hereunder with respect to such matter; it being
understood and agreed, for the avoidance of doubt, that any such consent of the
Indemnitor to any such consent to the entry of judgment or settlement shall not
be deemed to be an admission or acknowledgement that any Indemnitee is entitled
to indemnification hereunder with respect to any such Third Party Claim.
 
13.7 Determination of Loss Amount. The amount of any Loss subject to
indemnification under Section 13.2.1 or 13.4.1 shall be calculated net of (a)
any Tax Benefit inuring to Buyer or Shareholder, as applicable, and/or any of
their respective Affiliates on account of such Loss, and (b) any insurance
proceeds or other third party indemnification or reimbursement proceeds actually
recovered on account of such Loss. If Buyer or Shareholder and/or any of their
respective Affiliates realizes a Tax Benefit on account of such Loss and such
Tax Benefit was not included in the computation of the Loss, Buyer or
Shareholder, as applicable, shall within ten (10) days of filing the Tax Return
claiming the Tax Benefit (or, to the extent the Tax Benefit is in the form of a
refund, within ten (10) days of receiving the refund from the Governmental
Entity) pay to the other party the amount of such Tax Benefit. Each party shall
take all commercially reasonable actions (and shall cause its Affiliates to take
all commercially reasonable actions) to timely claim any Tax Benefit that shall
reduce the amount of a Loss, or give rise to a payment to or for the benefit of
the other party, under this Section 13.7. Buyer and Shareholder shall, and shall
cause their respective Affiliates to, seek full recovery under all insurance
policies and other third-party agreements covering any Loss to the same extent
as they would if such Loss were not subject to indemnification hereunder. In the
event that an insurance recovery or a recovery under any other third-party
agreement is made by Buyer or the Shareholder and/or any of their respective
Affiliates with respect to any Loss for which any Buyer Indemnified Party or any
Shareholder Indemnified Party, as applicable, has been indemnified hereunder,
then a payment equal to the aggregate amount of the recovery shall be made
promptly by Buyer or the Shareholder, as applicable to the other party for the
benefit of the other party. The Shareholder shall be subrogated to all rights of
Buyer, the Companies and the Companies’ Subsidiaries in respect of any Losses
indemnified by the Shareholder. The Buyer shall be subrogated to all rights of
the Shareholder in respect of any Losses indemnified by the Buyer.
 
 
53

--------------------------------------------------------------------------------

 
13.8 Expiration of Indemnification. No Person shall be liable for any claim for
indemnification under Section 13.2.1 or Section 13.4.1 unless written notice
(stating in reasonable detail the nature of, and factual and legal basis for,
any such claim for indemnification, and the provisions of this Agreement upon
which such claim for indemnification is made) is delivered by the Person seeking
indemnification to the Person from whom indemnification is sought prior to the
expiration of the applicable Survival Period, in which case the representation,
warranty, covenant or agreement which is the subject of such claim shall
survive, to the extent of such claim only, until such claim is resolved, whether
or not the amount of the Losses resulting from such breach has been finally
determined at the time the notice is given.
 
13.9 Effect of Failure to Close. For the avoidance of doubt, notwithstanding
anything to the contrary in this Article 13, nothing herein shall prohibit any
Party from suing another or limit the amount of recovery for breach of contract
as a result of the other failing to consummate the transactions described in
this Agreement upon the satisfaction or waiver of its conditions precedent to
Closing.
 
ARTICLE 14
TERMINATION
 
This Agreement and the transactions contemplated herein may be terminated at any
time prior to the Effective Time by the mutual written agreement of Shareholder
and Buyer. In addition, either Shareholder or Buyer may terminate this Agreement
prior to the Effective Time if the other party fails to satisfy the conditions
applicable to such party (under Article 8 or Article 9, as the case may be) by
July 1, 2014.
 
In the event of such a termination, this Agreement shall be rendered void and of
no further force or effect, without any liability on the part of any of the
parties hereto or their respective owners, directors, officers or employees,
except the obligations of each party to preserve the confidentiality of
documents, certificates, and information furnished to such party pursuant hereto
and for any obligation or liability of any party based on or arising from any
breach or default by such party with respect to its representations, warranties,
covenants or agreements contained in related agreements.
 
 
54

--------------------------------------------------------------------------------

 
ARTICLE 15
MISCELLANEOUS
 
15.1 Specific Performance. The Shareholder and the Companies agree that the
Buyer shall have the right, in addition to any other rights and remedies
existing in its favor, to enforce its rights and the obligations of the
Shareholder and the Companies hereunder not only by an action or actions for
damages but also by an action or actions for specific performance, injunctive
and/or other equitable relief. Furthermore, the Buyer agrees that the
Shareholder and the Companies shall have the right, in addition to any other
rights and remedies existing in their favor, to enforce their rights and the
obligations of the Buyer hereunder not only by an action or actions for damages
but also by an action or actions for specific performance, injunctive and/or
other equitable relief.
 
15.2 Notices. All notices, requests, demands and other communications required
or permitted to be given or made under this Agreement shall be in writing and
shall be deemed delivered (a) on the date of personal delivery or transmission
by confirmed telegram or confirmed facsimile transmission, (b) on the third
(3rd) business day following the date of deposit in the United States mail,
postage prepaid, by registered or certified mail, return receipt requested, (c)
on the first (1st) business day following the date of delivery to a
nationally-recognized overnight courier service, or (d) by e-mail, in each case
addressed as follows, or to such other address, Person or entity as either party
shall designate by notice to the other in accordance herewith:
 
If to Buyer, the Companies or LHC, addressed to:                          LHC
Group, Inc.
420 West Pinhook Road, Suite A
Layfayette, LA 70503
Attention:  Joshua L. Proffitt General Counsel
Facsimile: (337) 235-8037
E-mail: Josh.Proffitt@lhcgroup.com
 
With a copy
to:                                                                     Jones
Walker LLP
201 St. Charles Avenue, 51st Floor
New Orleans, LA 70170
Attention: Allison C. Bell
Facsimile: (504) 589-8596
E-mail: abell@joneswalker.com
 
If to Shareholder or BioScrip, addressed
to:                                    BioScrip, Inc.
100 Clearbrook Road
Elmsford, NY 10523
Attention: Kimberlee Seah General Counsel
Facsimile: (914) 345-8122
E-mail: Kimberlee.Seah@bioscrip.com
 
 
55

--------------------------------------------------------------------------------

 
With a copy
to:                                                                     Polsinelli
PC
100 South Fourth Street, Suite 1000
St. Louis, MO 63102
Attention: Mark H. Goran
Facsimile: (314) 754-9465
E-mail: mgoran@polsinelli.com
 
15.3 Waiver. The failure of any party to insist, in any one or more instances,
on performance of any of the terms and conditions of this Agreement shall not be
construed as a waiver or relinquishment of any rights granted hereunder or of
the future performance of any such term, covenant or condition, but the
obligations of the parties with respect thereto shall continue in full force and
effect.
 
15.4 Third Parties. None of the provisions of this Agreement shall confer rights
or benefits as third party beneficiaries or otherwise upon any party that is not
expressly a party to this Agreement, and the provisions of this Agreement shall
not be enforceable by any such third party.
 
15.5 Severability. If any part of this Agreement should be determined to be
invalid, unenforceable, or contrary to Law, that part shall be amended, if
possible, to conform to Law, and if amendment is not possible, that part shall
be deleted and other parts of this Agreement shall remain fully effective, but
only if, and to the extent, such modification or deletion would not materially
and adversely frustrate the parties’ essential objectives as expressed in this
Agreement.
 
15.6 Amendment. This Agreement may be amended, supplemented, altered or modified
at any time only by a written instrument duly executed by Shareholder and Buyer.
 
15.7 Counterparts. This Agreement may be executed simultaneously in any number
of counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument. The parties to this
Agreement may deliver their executed counterparts by facsimile or other
electronic means, provided that original signatures are delivered by U.S. Mail
promptly thereafter.
 
15.8 Headings. The headings contained in this Agreement have been inserted for
the convenience of reference only and shall in no way restrict or modify any of
the terms or provisions hereof.
 
15.9 Entire Agreement. This Agreement (including the schedules and exhibits
hereto, and all other agreements and documents executed in connection herewith)
constitutes the entire agreement among the parties hereto with respect to the
subject hereof.
 
15.10 Successors and Assigns. All terms and provisions of this Agreement shall
be binding upon and inure to the benefit of and be enforceable by the respective
successors and permitted assigns of the parties hereto, whether so expressed or
not.
 
15.11 Governing Law; Jurisdiction. The parties specifically agree that this
Agreement shall in all respects be interpreted, read construed and governed by
the internal Laws of the State of Delaware, exclusive of its conflicts of law
rules. Any party hereto shall be entitled to bring an action to enforce any
provision of, or based on any right arising out of, relating to or in connection
with, this Agreement, in law or at equity for specific performance, or for any
other remedy or damages, in the United States District Court for the District of
Delaware, situated in Wilmington, Delaware or any Delaware court sitting in New
Castle County, Delaware. Each party hereto expressly agrees to waive any
challenge to either jurisdiction or venue in any of the aforementioned courts.
The prevailing party in any such action shall be entitled to recover all
attorneys’ fees of pursuing or defending an action under this Agreement.
 
 
56

--------------------------------------------------------------------------------

 
15.12 BioScrip Guarantee.
 
15.12.1 BioScrip hereby guarantees to the Buyer the payment in full of all
amounts when due and owing (i) by Shareholder under this Agreement and any
amendments hereto, including Shareholder’s obligations to indemnify the Buyer
Indemnified Parties in accordance with Article 13; (ii) incurred in connection
with any actions, suits or proceedings initiated to enforce the provisions of
this Section 15.12; and (iii) with respect to damages for breach of contract as
a result of the Shareholder failing to consummate the transactions described in
this Agreement upon the satisfaction or waiver of its conditions precedent to
Closing (collectively, the “BioScrip Obligations” and each, individually, a
“BioScrip Obligation”).
 
15.12.2 BioScrip covenants and agrees that if at any time the Shareholder
defaults in the payment of any BioScrip Obligation, BioScrip shall promptly,
upon notice from a Buyer Indemnified Party, pay, or cause the payment of, such
BioScrip Obligation.
 
15.12.3 The obligations of BioScrip under this Section 15.12 are absolute and
unconditional, present and continuing, and shall not be affected, modified or
impaired or prejudiced upon the happening from time to time of any one or more
of the following events:
 
(i) the extension of time for payment of any amounts due or of the time for
performance of any of the BioScrip Obligations;
 
(ii) the modification or amendment (whether material or otherwise) of any of the
BioScrip Obligations;
 
(iii) the failure, omission, delay or lack on the part of the Buyers to enforce,
ascertain or exercise any right, power or remedy under or pursuant to the terms
of this Agreement;
 
(iv) the fact that BioScrip may at any time in the future dispose of all or any
part of its interest in Shareholder; or
 
(v) the bankruptcy, insolvency, winding up, dissolution, liquidation,
administration, reorganization or other similar or dissimilar failure or
financial disability of Shareholder.
 
 
57

--------------------------------------------------------------------------------

 
15.13 LHC Guarantee.
 
15.13.1 LHC hereby guarantees to the Shareholder the payment in full of all
amounts when due and owing (i) by Buyer under this Agreement and any amendments
hereto, including Buyer’s obligations to indemnify the Shareholder Indemnified
Parties in accordance with Article 13; (ii) incurred in connection with any
actions, suits or proceedings initiated to enforce the provisions of this
Section 15.12; and (iii) with respect to damages for breach of contract as a
result of the Buyer failing to consummate the transactions described in this
Agreement upon the satisfaction or waiver of its conditions precedent to Closing
(collectively, the “LHC Obligations” and each, individually, a “LHC
Obligation”).
 
15.13.2 LHC covenants and agrees that if at any time Buyer defaults in the
payment of any LHC Obligation, LHC shall promptly, upon notice from a
Shareholder Indemnified Party, pay, or cause the payment of, such LHC
Obligation.
 
15.13.3 The obligations of LHC under this Section 15.13 are absolute and
unconditional, present and continuing, and shall not be affected, modified or
impaired or prejudiced upon the happening from time to time of any one or more
of the following events:
 
(i) the extension of time for payment of any amounts due or of the time for
performance of any of the LHC Obligations;
 
(ii) the modification or amendment (whether material or otherwise) of any of the
LHC Obligations;
 
(iii) the failure, omission, delay or lack on the part of the Shareholder to
enforce, ascertain or exercise any right, power or remedy under or pursuant to
the terms of this Agreement;
 
(iv) the fact that LHC may at any time in the future dispose of all or any part
of its interest in the Buyers; or
 
(v) the bankruptcy, insolvency, winding up, dissolution, liquidation,
administration, reorganization or other similar or dissimilar failure or
financial disability of the Buyers.
 

[Remainder of page reserved intentionally]
 

*                      *                      *                      *                      *
 
 
58

--------------------------------------------------------------------------------

 
IN WITNESS WHEREOF, the parties have entered into this Agreement as of the date
first written above.
 
[sign1.gif]
 
 
 
 

--------------------------------------------------------------------------------

 
LHC (solely with respect to Sections 10.4, 10.6, 12.3 and 15.13 of this
Agreement):

 
[sign2.gif]

 
 
 
 
 
[Remainder of page reserved intentionally; Signatures continue on following
page.]
 
 
 

--------------------------------------------------------------------------------

 
 
[sign3.gif]